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SUMMARY
Deuterated tyrosine has been used to study tyrosine
metabolism In one normal and two patients with rare forms of
non-hepatic tyroslnaemia.

The labelled tyrosine was Ingested

orally, after which urine and serum samples were examined by
6C-MS at regular Intervals for residual labelled tyrosine and
tyros i ne metaboIi tes.
The derivatives of choice for GC-MS were the 0-methyl
ether of the N-neopenty11 dene tyrosine methyl ester, the
trimethyl silyl derivatives of the phenolic acids and the
N-trifluoroacetyl Otrimethyl silyl derivatives of the
catecholamines.
It was shown that loading rates of 220 pmoles of
deuterated tyrosine/kg body weight were adequate for precise
measurement of the stable isotope content of urinary and serum
tyrosine and tyrosine metabolites.

This load approximates to

that provided by a protein containing meal, so these stable
isotope load studies can be claimed to mimic physiological
conditions.
The amount of deuterated substrate used In this study was
not considered a health risk, as even complete isotope retention
In vivo would only Increase the natural abundance in the body
by less than 20%.
Deuteration experiments were made with a combined GC-MS
Instrument operating under computer control using time averaging

and mass fragmentometry.

The studies on the two patients and

a normal control were carried out under conditions of high and
low tyrosine loads. The results of these studies defined the
biochemical lesion In one patient at the site of p-hydroxyphenylpyruvlc acid oxidase.

Although the site of the primary

defect In the other patient has not been established. It Is
clear that It Is not at the site of p-hydroxyphenyI pyruvic
acid oxidase.

This patient suffered from substrate Inhibition

of p-hydroxyphenyI pyruvic acid oxidase when on a normal diet.
Resolution of the clinical and biochemical symptoms with
disappearance of the Inhibition of p-hydroxyphenyI pyruvic acid
oxidase occurred with the Implementation of a diet low In
phenylalanine and tyrosine.

Although the fundamental defect

In this patient Is not resolved, the findings appear compatible
with a defect In hepatic soluble tyrosine aminotransferase.

The

rates of deuteratlon of tyrosine metabolites have allowed us to
distinguish between Individuals having different clinical
manifestations but similar biochemical abnormalities.

INTRODUCTION

I n 1908, Garrod cof ned the term " i nbom error of metabo I! sm"
to describe his studies on four conditions: albinism, alkaptonuria,
pentosuria and cystinurla.^

He postulated that an absence or

deficiency of a specific enzyme can cause abnormal production of
an Intermediate which Is either excreted In the urine or stored In
the tissues or organs.

It Is now known that as a consequence of

such a deficiency, biochemical changes may be reflected indifferent
ways:

(I) there may be a complete absence of the final product of

the pathway as In the lack of melanin in albinism;

(11) there may

be an accumulation of an intermediate metabolite for which there is
no significant alternative pathway such as glycogen storage disorders
In which glycogen Is made but cannot be utilised;

(ill) there may

be an accumulation of products of an alternative and ordinarily
minor pathway of metabolism as In phenyketonuria, leading to
excretion of large amounts of a compound ordinarily produced In
trace amounts. Garrod's predictions have been amply confirmed In
the past half century^'and more than a hundred and fifty "genetic
defects" have been described**'^.

It is probable that many other

human diseases of unknown aetiology will eventually be ascribed to
congenital enzymatic defects.
Until recently, the Identification of specifIc metabolites
depended exclusively on either a few qualitative chemical tests or
on the preparation of derivatives which could be characterised by
simple chemical and physical means.

Included In these tests® Is
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Figure t * Growth of knowledge about Inborn errors of amino acid metabolism.
The open circles Indícate findings made In the pre-partltlon
chromatography era; filled circles reflect findings derived from
the use of partition chromatography on filter paper and the
nlnhydrln stain to locate amino acids In biological fluids; the
squares Indicate at least a dozen diseases Identified through the
application of GC/MS methods to biological fluids.

the ferric chloride test for the detection of phenols, the cyanide
nitroprusslde reagent for the detection of disulphldes and the use
of Phenylhydrazine for the detection of keto-aclds.

In the era

before 1940, the limited range of chemical tests aval Iab le
accounted for the few known Inborn errors of metabolism.
In 1946, Dent^»® published his papers on paper partition
chromatography of amino acids In serum and urine.

When coupled with

the sensitive and specific nlnhydrln stain for amino acids, this new
technique provided an excel lent method for the screening and
detection of metabolic diseases, and thereby accounted for the
large numbers of new diseases which were discovered In the period
1945 to 1967 (Figure I, after Scrlver®).

However, the sensitivity

and effectiveness of Dent's technique compared to other tests In
use at that time, produced the false Impression that most genetic
defects were due to aberrant metabolism of nlnhydrln positive
compounds.

It Is worth noting that by 1970, the rate of Increase

of new discoveries had started to decline because by this time,
most of the nlnhydrln positive compounds which accumulate, because
of defective metabolism, had already been characterised.

It was

not until new Instrumental developments, particularly gas
chromatography (GC) and mass spectrometry (MS) were applied to
biomedical problems that the pace of discovery of new metabolic
disorders started to Increase again.

This new technology has

permitted the Identification of many diseases where the accumulated
metabolites^® do not react with nlnhydrln.

GC provides the

advantages of high sensitivity with the abl Hty to resolve Individual
components of a complex mixture and It also offers speed and
simplicity of operation at a low cost. MS however, apart from the
high cost and complexity, has the capability of Identification of
unknown compounds from their spectra and also provides qualitative
and quantitative measurements of volati le compounds with a high
degree of sensitivity and specificity.

In particular, the use

of a GC In combination with a MS offers the clinical chemist a
most powerful tool for the Investigation of metabolic disease.
At Its present stage of development, GC-MS Is too difficult to
Implement In clinical practice on a routine basis and Is only
suitable for the detalled study of a selected number of cases.
It has found greatest use In the diagnosis and study of those
cases In which organic acids accumulate In the body fluids.
It Is quite difficult to outline any rigid criteria for the
selection of patients for such an analysis. However, It has been
shown that blood and urine from young children suffering from such
symptoms as failure to thrive, developmental and psychomotor
retardation, seizures starting In early infancy, convulsion or
Irritability and acidosis are most suitable for study by the
GC-MS technique.

Affected newborn Infants constitute an

Important group of suitable subjects for special Investigation,
since a number of genetic defects are known to lead to early
death or to gross mental retardation. The clinical manifestations
produced by such Inborn errors of metabolism vary tremendously.

Some, like pentosuria» fiRlRoglyclnurra and ^-Mlnofsobutyrfc
aciduria are harmless; others Including branch chain keto-aclduria,
phenylketonuria and gaiactosaemla lead to severe clinical disturbances
In Infancy which later result In early death or profound mental
deterioration.

The severity of the symptoms are usually related

to the toxicity and/or the rate of accumulation of specific
metabolites In blood and tissues. An early diagnosis often depends
on the detection and Identification of some of these metabolites.
Since death or mental retardation can often be prevented by an
early Implementation of a dietary regimen, such an analysis
becomes a valuable tool In the diagnosis and subsequent treatment
of metabolic disorders. Other compelling reasons for accurate
diagnosis concern the determination of possible heterozygosity In
siblings where genetic counselling would be beneficial.
The present clinical practice for metabolic screening Is to
rely on a battery of chemical tests^^-^^, which Include chromatographic
or electrophoretic separation of metabolites, colorlmetrlc and
spectrofluorometric measurements and microbiological tests. The
disadvantages of these clinical methods lie In their non specific
nature and on the total reliance of the analyst on the recognition
of characteristic patterns associated with some of the more common
metabolic disorders.

Since some therapeutic agents and dietary

supplements may give positive colour reactions with chromatographic
sprays, the clinical Interpretation of positive findings usually
needs a more detailed analytical tool for an unequivocal Identlflc-
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NAME OF DISEASE

ALCAPTONURIA

HOHOGENTISIC ACID

HYPERTRYPTOPHANEMIA

TRYPTOPHANE

CARNOSINEHIA

CARNOSINE

HYPERVALINEMIA

VALINE

ISOVALERIC ACIDEMIA

ISOVALERIC ACID* ^-HYDRCDCY-

NAHE OF DISEASE

CONGENITAL LACTACIDOSIS

LACTIC ACID

CYSTATHIONINURIA

CYSTATHIONINE

ISOVALERIC ACID«

CYSTINURIA

CYSTINE

SLVCINE

DIABETES NEULLTUS

ISOVALERYL-

GLUCOSE* ^-HYDROXYBUTYRIC

MAPLE SYRUP URINE

VALINE* LEUCINE*

ACID. ACETOACETIC ACID

DISEASE

C-KETOISOVALERIC ACID*

ISOLEUCINE*

ESSENTIAL FRUCTOSURIA

FRUCTOSE

TF-KETOISOCAPROIC

ESSENTIAL PENTOSURIA

L-XYLULOSE

RF-KETO-Z^METHYLVALERIC

GALACTOSEMIA

GALACTOSE* AMINO ACIDS

METHYLMALONIC ACIDEMIA

METHYLMALONIC A C I D

L-GLYCERIC ACIDURIA

L-GLYCERIC ACID* OXALIC ACID

NON-KETOTIC HYPER-

GCYCINE

HARTNUP DISEASE

NEUTRAL AMINO ACIDS

GLYCINEMIA

HISTIDINE*

OAST-HOUSE DISEASE

HISTIOINEHIA
HOMOCYSTINURIA
F-HYDROXYISOVALERIC

IMIDAZOLEACETIC

ORNITHINEMIA

ORNITHINE

HOMOCYSTINE* METHIONINE

OROTIC ACIDURIA

OROTIC ACID

PHENYLKETONURIA

PHENYLALANINE*

PHENYL-

P-HETHYLCROTONYLGLYCINE

PYRUVIC ACID*

HYDROXYLYSINURIA

HYDROXYLSINE

ACETIC ACID

HYDRGXYPROLINEMIA

HYDROXYPROLINE

PROPIONIC ACIDEMIA

PROPIONIC ACID

HYPER-P-AUNINEMIA

^-ALANINE, P-AMLNOISOT-

PYROGLJUTAMIC ACIDURIA

PYROGLUTAMIC ACID

ACIDURIA & ^-METHYLCROTONYLGLYCINURIA

ACID

«F-HYDROXYBUTYRTC A C I D

ACID
^ - H Y D R O X Y I S O VALERIC ACID*

ACID*

PHENYLLACTIC

ACID* O-HYDROXYPHENYL-

(PYRROLIDON-2-CARBOXYLIC
ACID)

BUTYRIC ACID* Y - A M I N O -

BUTYRIC ACID
HYPERLYSINEMIA

LYSINE

REFSUM'S DISEASE

PHYTANIC ACID

HYPERMETHIONINEMLA

METHIONINE* RF-KETO-Ì-

RENAL GLYCOSURIA

FILUCOSE

METHIOLBUTYRIC ACID

SHORT CHAIN FATTY

BUTYRIC ACID* CAPROIC ACID

OXALIC ACID* GLYCOLIC ACID*

ACIDEMIA

6LY0XYLIC ACID

TYROSINOSIS

HYPEROXAUIRIA

TYROSINE* P-HYDROXYPHENYL-

HYPERPROLINEMIA

PROLINE

PYRUVIC ACID* P-HYDROXY-

HYPERSARCOSINEMIA

SARCOSINE

PHENYLLACTIC A C I D

FI6URE 2.

INBORN ERRORS OF METABOLISM OETECTABL£ BY THE GC-FLS SYSTEM.

atlon of metabolites extracted from biological samples. With
this technique, it is now possible to detect a large number of known
errors of metabollsm^'^»^^ (Figure 2).
Whilst the application of 6C«*MS to the study of human disease
may appear exciting and relatively simple at first glance, there
are, however, many difficulties and pitfalls associated with this
technique.

VoIatlIe contaminants which may be confused with

metabolites on gas chromatograms arise from plasticizers^®,
anticoagulants^^, solvent Impurities^®, bacterial contamlnants^^»^®,
dietary factors and drugs and their metabolites^**'^^»^^.

Apart

from artifacts arising from these, the complexity of biological
specimens also pose problems, since the several hundred metabolites
normally present In these fluids cannot be readily separated by GC
from each other and a preliminary separation Is normally necessary.
Thus, Jellum et al^** routinely extract and examine eight separate
blood and urine fractions for diagnostic purposes, whilst other
workers^^"*^® restrict themselves to a single extract containing
a specific class of metabolites of interest.
Unfortunately, most biologically Interesting compounds are
not sufficiently volatile or thermally stable for GC separation.
This problem can be overcome by making these compounds less polar
by chemical modification which is generally referred to as
derivatisation.

To be of value such a procedure should be

chemically simple and should result In quantitative conversion
of the metabolite of interest. MethylatIon with dlazomethane Is

TABLE I.

A LIST OF SOME DERIVATISATION PROCEDURES FOR GC-MS ANALYSIS,

REACTANT GROUP

REAGENT

REACTION PRODUCT

R-OH

HEXAMETHYLDISILAZANE, TRIMETHYL-CHLOROSILANE/ ETC.

R-0-SI(CH3)

R-CO

METHYL

0-METHYLOXIMES

HYDROXYLAMINE

CF3C

>

RCOOH

ENOL TRIFLUOROACETATES

CHJNJ

RCOOHE

N,0-BIS (TRIMETHYLSLLYI.) ACETAMIDE

RC00SI(CH3)3

OTHER SJLYLATION
REAGENTS

RNHJ.
RR'NH

H(CF2)„CH20H

RC00CH2<CF2>N"

CF3C<°
>

J>NC0CF3

CF3<O
THIAMINE

HYDROXY
KETO STEROIDS

Yo

,21-DIHYDROXY
-KETOSTEROIDS

CORTICOSTEROIDS

SILYUTION
REAGENTS

-GOOSICCFIGL
-NHSI(CH,)
3^3

METHYL
HYDROXYALMINE
AND SILYLATION
REAGENT

CH20SI(CH3)3
¿-NOCH,

DIMETHYL
METHOXYCHLOROSILANE

METHYL
BORONIC ACID

-0

^^BCH.

PHOSPHORYLETHYLAMINE

SILYLATION
REAGENT

DISACCHARIDES

BOROHYDRIDE OR
BORODEUTERIDE
PLUS TRIMETHYL
SILANE

REDUCED TO ALOITOLS
AND SILYLATED

SUGARS IN
LIPOPOLYSACCHARIDES

HEXAMETHYLDISILAZANE
AND TRIMETHYLCHLOROSILANE

PERSILYLATED
SUGARS

AMINO ACIDS

BUTANOL OR PROPANOL.
TRIFLUOROACETIC ANHYDRIDE

N-TFA ESTER

SILYLATION

TMSOXP^O
T M S O ^ ^0-(CH2)2NTMS

M
one such procedure which Is experimentally simple, but suffers from
the disadvantage that a multiplicity of methylatlon products may be
formed with some metabolItes^^»^®.

Furthermore, the Inherent

dangers associated with the handling of dlazomethane make It
unsuitable for many clinical laboratories*

Despite these

disadvantages, some laboratories have used dlazomethane derIvatIsatIon
of acids and other metabolites with some success^**»^^"^*^. The other
commonly used reagents are the trimethylsllylatlon reagents which
have gained wide acceptance since derivatives are formed readily,
quantitatively and conveniently with a wide range of compounds.
SI lylatlon has been used for the GC analysis of sterlods^®""^®,
aromatic aclds^^»^®»^^*'*^, nucleic acid components**^""*^^, amino
acids'^®*'»®, carbohydrates'»amlnes^®»^!^ organic aclds25-28,53
and vitamins^**. The reagent of choice Is bis (trimethyIsl lyl)
trifluoroacetamlde (BSTFA)^®, which Is one of the most potent
sllylating agents available and which has the added advantage that
Its reaction byproducts are highly volatile and elute with the
solvent and excess reagent.

Furthermore, sHyl derivatives are

stable for several months at room temperature, provided moisture
Is strictly excluded. More recently, specific combinations of
derlvatlslng agents have been employed for polyfunctlonal compounds^®
for special applications (Table I).
One of the most recent application of the GC-MS technique Is
In the use of stable Isotope labelled substrates for the study of
metabolic pathways^^"^®. This tool permits the Investigator to

determine both qualItatIve Iy and quantÍtatfveÍy the position of
the Isotope label In the substrate and Its metabolite.

The heavy

Isotope of greatest Interest to the biochemist are deuterium (^H),
carbon-13 O^C), nítrogen-15 i'^^H) and oxygen-18 0^0).

These

Isotopes are stable, they are harmless to man when they are
Incorporated In suitable substrates In the amounts required for
metabolic studies and they can be used to study human metabolism
In vivo In both normal and diseased states*
Despite their great potential utility, the use of stable
Isotopes In clinical medicine has virtually been neglected.

This

has been brought about by the unavailability of labelled substrates
at realistic prices.

In addition, the mass spectrometer equipment

required to measure Isotope abundances was too expensive and too
difficult to operate and maintain for most biologically orientated
departments.
In recent years, the use of stable isotopes has begun to
expand, largely as a result of the increased commercial availability
of a wider range of labelled compounds.

Apart from this, more

reliable mass spectrometers have become available and the analytical
techniques for the detection and assay of stable Isotopes have
become Increasingly refined and more widely available.

One such

technique is mass fragmentómetry, which Is Inherently more
sensitive than conventional GC-MS because the mass spectrometer
can be made to record the signal from only a few Ions rather
than scan the mass range needed for a complete mass spectrum.

By

continuous recording of m/e values corresponding to characteristic
fragments of the expected metabolites. It Is possible to eliminate
or at least diminish the background signal and thus reduce the
Influence of Interfering compounds. Characterisation of the
metabolites Is based upon the presence of selected mass numbers,
their relative Intensities and retention times. Thus the MS Is
used as a GC detector with Improved selectivity compared to
single Ion detection. The technique has been shown to be so
sensitive that picogram dO"^** to

moles) can be detected.

The greatest single disadvantage of stable Isotopes for the
study of metabolism Is the lack of a simple sensitive. Inexpensive
Isotope-specific method of quantitation comparable to liquid
scTntIIlatlon counting.

With radioactive labels there Is a

convenient, inexpensive and sensitive non-compound specific means
of detection, that of detecting the emitted radiation.

Radiation

detectors lack specificity, however, since the amount of Isotope
present In the sample Is measured without regard to Its chemical
or molecular form. The detection of stable Isotope requires more
expensive instrumentation and Is associated with greater analytical
complexity, but the recent development of mass fragmentometry provides
a molecularly specific detection method whose sensitivity now rivals
that of radio-Isotopes In favourable circumstances, e.g. chlorpromazine
has been detected In picogram amunts^^.

This development has made

It possible for the medical and clinical researcher to attempt
experiments with stable Isotope label led substrates.

Biochemical research In the past decades has led to our present
understanding of the chemical basis of certain genetic diseases.
This knowledge has been mainly brought about by the use of
radioactive tracers to study metabolic pathways In vivo and to
locate specific blockages.

A serious consequence of the use of

radioisotopes Is the risk of Ionising radiation to the subjects
Involved. Because of this hazard, studies involving the use
^^ radioisotopes In vivo are not permitted on healthy subjects
and users of these tracers are obliged to adhere to standards
of radiation safety Imposed by the Health authorities.

In

addition» the conventional methods of measuring radioactivity,
where the components are usually separated by paper, thin layer
and column chromatography and then measured In a liquid
scintillation counter are both tedious and time consuming.

In

addition, it Is not possible to determine the position of the
label within a molecule, and It Is not possible to identify or
confirm the structure of the metabolites.

However, these

problems can be readily overcome by the use of stable non-radloactlve
isotopes with the combined use of GC-MS. The procedure offers the
advantages In that the GC can separate a complex mixture Into Its
components, while the MS can often determine and Identify the
position of the label within each component. We have made use of
stable Isotope labelled substrates to study tyrosine metabolism
In two non-hepatic tyrosinaemlcs and an adult control. These
patients were particularly suitable for study as they presented

us with different clinical symptoms but at the same time had
surprisingly similar biochemical abnormalities.

DISCUSSION

TABLE 2 .

B I O C H E M I C A L F E A T U R E S O F P A T I E N T S ON U N R E S T R I C T E D

DIETS.

SUBJECT
P.R.

J.L.

MAXIMUM OF
NORMAL RANGE

SERUM TYROSINE

CONCENTRATION

1.36

1.52

0.07

TYROSINE

0.121

0.20

0.117

NAT

0.057

0.031

0.002

PHPAA

0.177

0.117

0.005

PHPLA

1.51

0.863

0.001

PHPPA

L.ILL

0.151

NOT DETECTED

DOPA

0.108 X 10"5

NORMAL

0.038 X 10"'

DOPAMINE

2.63 X

NORMAL

1.23 X 10"5

NORADRENALINE

NORMAL

NORMAL

0.267 X 1 0 " '

ADRENALINE

NORMAL

NORMAL

0.082 X 10"'

(MILLIMOUR)
URINARY

METABOLITES

(MILLIMOLES/MIAIMOLE

CREATININE)

10"'

O\

The two patients In this study were from the Royal Melbourne
ChiIdrens' Hospital, Melbourne, Victoria.

They have been Invest-

igated over a number of years and a case report on one had already
appeared In the literature®^.

The two patients presented something

of an anomaly In that they had different clinical symptoms, but at
the same time had surprisingly similar biochemical abnormalities.
Neither patient had any evidence of liver disease and serum and
urine methionine levels were normal. One was a 9 year old girl
(P.R.) of low normal Intelligence who suffered with chronic
hyperkeratosis of the palms and soles and with recurrent
pseudoherpetIc keratitis, while the other was an adult mentally
retarded 38 year old man (J.L.), who showed a minimal hyperkeratosis
of the soles and no eye lesions.

When untreated, both patients

had elevated serum and urinary tyrosine and phenolic aciduria with
elevated p-hydroxyphenylacetic acid (pHPAA), p-hydroxyphenyI lactic
acid (pHPLA) and p-hydroxypheny I pyruvic acid (pHPPAXTable 2).

J.L.

has been reported to have Increased levels of dlhydroxyphenylalanine
(dopa) and dlhydroxyphenylethylamlne (dopamine) with normal levels
of urinary adrenaline and noradrenaline®^.

There was no detectable

elevated excretion of catechols In patient P.R., and In neither
patient was there an Increased excretion of p-tyramlne.
The principal pathways of tyrosine metaboI Ism are illustrated
In Fig. 3.

The oxidative pathway Is shown In bold arrows and

accounts for the major catabollsm of this amino acid. The first
step Involves the oxidation of tyrosine which Is catalysed

HO
HO

OH

CH^H^-NHCf;^
DOPAMINE

CHCHjNHCl^

\

ADRENALINE

NORADRENALINE

HP-C^O

HO
HO -^^CHx^H-COOH

CH^CH-COOH

L DOPA

N ACETYL TYROSINE

NHj
HO

CHjCH-COOH

II

TYROSINE

HO-^^CH-CO-COOH
I

H0-<Q>-CH2-CH2-NH2
jpTYRAMINE
HO -<Q>-CH2C00H

pH PA A

pHPPA
•COOH
OH

HO -^^CH^^H-COOH

^

HG^

pHPLA

TCA cycle
FIGURE 3. METABOLISM OF TYROSINE
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principal fy In the Mver by ty*^slne aminotransferase (E.G. 2.6.1.5.)
to form pHPPA. This In turn Is oxidised to homogentlsic acid (HGA)
by p-hydroxyphenylpyruvic hydroxylase (E.C. 1.99.1.14). This Is
followed by catalytic oxidation of HGA by the enzyme homogentlsate
oxygenase (E.G. 1.99.2.5) to form metabolites which are eventualiy
oxidised via the tricarboxylic acid (TGA) cycle. Several Inherited
metabolic diseases are known to occur In this route. When the first
step In the oxidation of tyrosine Is Impaired» as In the "Oregan
type" of tyrosinaemla®^»®**, a disorder of transamination/ the
soluble (cytosol) form of tyrosine aminotransferase Is deficient.
Medes classic description of "tyrosinosis"®^ may also be attributed
to a block In this step.

If the enzyme pHPPA hydroxylase Is

deficient, transient neonatal tyros I naem I a or hereditary tyroslnaemla
may result. Transient neonatal tyroslnaemla^® Is of Interest
because It elucidates several Important facets of post natal enzyme
development whereas hereditary tyroslnaemla®^®^ Is a complex
disease with hepatic involvement accompanied by grave illness. A
deficiency or absence of the third enzyme homogentlsate oxidase
results In alcaptonurla, one of the classic Inborn errors of
metabolism described by Garrod at the turn of the century.^ The
minor pathways of tyrosine metabolism lead to catecholamines,
melanin, thyroid hormones and protein. The transamination step
Is usually rate limiting for tyrosine oxidation^® and although
It Is reversible, the equilibrium favours the keto acid formation
In vivo. Most of the pHPPA Is formed from tyrosine by the forward

reaction, but accumulation of this keto acid In the body tissues
and fluids for any reason will lead to synthesis of tyrosine by
reverse transamination.

Tyrosine aminotransferase exists In at

least two f o r m s ® * * b o t h of which are present In the liver,
kidney, brain, heart and muscle.

A soluble fonii of the enzyme

Is found In the cytosol whereas the other type Is present In the
mitochondria.

N-acetylatlon of tyrosine Is said to occur when

the plasma tyrosine concentrations exceed

Each of

these Inborn errors of metabolism described In the tyrosine
oxidative pathway results In a characteristic and dlagnostlcally
useful spectrum of Increased quantities of urinary aromatic acids.
The conflicting biochemical and clinical descriptions of the
two patients (J.L. and P.R.) In this study defied an easy
explanation as to the likely location of the biochemical leslon(s)
responsible for their disorders.

Resolution of the biochemical

defects by enzyme assays on liver tissue obtained from open section
operation could not be justified. An examination of the tyrosine
catabollc pathway and the metabolites that were excreted by our
patients showed the metabolism Involved here centred mainly on the
aromatic ring of tyrosine.

It was obviously desirable for us to

find a suitable label for the aromatic ring of tyrosine.
The literature suggested that hydrogen attached to an
aromatic ring such as benzene or aromatic polycycllcs are most
conveniently exchanged under mild conditions If Group VIII metals
such as platinum, palladium or Iridium are used as catalysts^®

In conjunction with deuterium oxide (D^O), Acid Induced exchange^^'^^
has also been shown to facilitate deuterium Incorporation Into the
aromatic ring. This method of deuteratlon of organic compounds by
Group VIM metal-catalysed exchange^® Is one of the oldest methods
known for the Introduction of deuterium Into organic molecules. We
attempted to deuterate tyrosine In D^O over platinum catalyst as
described by Murray.^^

Reactions were carried out In sealed

evacuated tubes using platinum catalyst which had been freshly
prepared by reduction of platinum dioxide with sodium borohydrlde.
The molar ratio of tyrosine:

platinum: D^O used was 6.7: 6.0: 4.5.

The reaction was allowed to proceed for 4 days at 70®C. Platinum
was removed by filtration, and the deuterium content of the tyrosine
was examined by GC-MS as the 0-methyl neopentyl Idene tyrosine
methyl ester. The analysis showed that the product contained 55%
unlabel led, 50% dideuterated and \6% tetradeuterated In the aromatic
ring.

Because only 80 mg of tyrosine was used for this deuteratlon

reaction and the anticipated In vivo study required several grams
of labelled substrate, we decided to Increase the concentration of
tyrosine for the labelling experiment.

But under these conditions,

the extent of deuterium exchange was decreased markedly, probably
due to the presence of substantial amounts of undissolved tyrosine
In the reaction mixture which did not exchange with 0^0.

In view

of the slowness of the reaction and the low solubility of tyrosine
under these conditions, this procedure did not offer a viable
method for the preparation of grams amounts of labelled tyrosine.

3-4N

OH

hA^H
CH^
CH-NH2

HCl

D2O

in

OH

TOOT

9^2
CH NH2
COOH

COOH

PRODUCT:-

80%

D^ SPECIES

¡9%

D^ SPECiES

I"/»

Dq SPECIES

FIGURE 4. PREPARATION OF DEUTERATED
TYROSINE

Because of the low solubility of tyrosine (4*I4 milMmoies/
litre of water at 40^0, we decided to Increase the solubility of
tyrosine by making use of a suitable derivative of tyrosine for
deuteratlon by catalytic exchange. N-acetyl tyrosine which Is
more soluble than tyrosine was prepared by the procedure of
Greensteln and Wlnltz®®. We found a considerable Improvement In
the yield of the reaction when N-acetyl tyrosine was substituted
as the substrate*

Using the same conditions as described for

tyrosine, two atoms of deuterium were readily Introduced Into
the aromatic ring after 4 days at 70®C. Unfortunately, enzymatic
hydrolysis of the N-acetyl moiety, using acylase I or carboxypeptidase
was extremely slow, and the hydrolysis did not go to completion,
whilst acid hydrolysis In 6N HCI at lOO^C for three hours resulted
In a complete loss of the deuterium label from the aromatic ring,
presumably by a back exchange reaction. This HCI-catalysed reaction,
however, suggested that tyrosine might be suitably labelled by an
acid catalyst reaction with D^O.

In this fashion deuterated

tyrosine was successfully prepared by refluxlng tyrosine In D^O
made 3-4N through the addition of HCI gas. Equilibrium of the
reaction was reached after 6 hours (Fig. 4), and the Identity of
the product was confirmed by nuclear magnetic resonance (NMR)
spectroscopy and GC-MS. The position of the deuterium atoms In the
aromatic ring was shown to be ortho to the hydroxy I function by
spectroscopy as the 4 proton quartet In the undeuterated
tyrosine sample was converted to a 2 proton singlet In the

(a)

Non Deute rated

/W
10

8

(b) Deuterated
Tyrosine

iO

8

7

6

ppm
Figure 5. N.M.R. Spectra of (a) Non Deuterated Tyrosine,
(b) Deuterated Tyrosine.

deuterated sample (Figure 5 ) .

The GC-MS of deuterated tyrosine

as the 0-methyl N-neopenty11 dene methyl ester showed that two
deuterium atoms were Introduced Into the aromatic ring since the
substituted tropyllum Ion at m/e 121 a.m.u. CH3C-O-C6H5-CH23 In
unlabel led tyrosine was converted to 123 a.m.u* In deuterated
tyrosine (Figure

After having successfully prepared

deuterated tyrosine in grams amounts by this route, we found a
report by Martin and MoriIno®^ describing similar work.
a molar ratio of tyrosine:

Using

D2O: HCI of 0,14:15.6:1.0, we

found the product of the reaction consisted of 80jf of the D2specles, \9% of the Oj-specles and \% unlabelled tyrosine.

The

optical purity of the deuterium labelled tyrosine was confirmed
by polarlmetry.

This reaction afforded an easy and cheap

preparation of large quantities (^^10 grams) of deuterated
tyrosine.
One Inherent difficulty In using deuterium or tritium labelled
substrates for metabolic studies Is the posslblIIty of back
exchange reactions In the body.

Both chemical and enzymatic

exchange reactions are possible, either of which would result In
the loss of the deuterium label from the aromatic ring.

Since

labelled tyrosine was syntheslsed by an exchange reaction In
acid conditions, we checked the possibility of back exchange
under the conditions existing In vivo In the stomach (pH I) by
Incubating the labelled tyrosine In IN HCI at 38®C. The
experiment showed that no loss of label occurred over a period of
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24 hours.

The known metabolic pathway of tyrosine, shows only

one possible site for en2ymatic exchange of the deuterium label.
This takes place during the hydroxylatlon of the phenolic ring
of tyrosine to dopa. In which one deuterium atom wl11 be lost.
In order to study tyrosine metabolism with Its deuterated
analogue, suitable analytical procedures for the Isolation and
determination of the amino acid and Its major metabol Ic products
had to be developed.

Although many chemical procedures for

this purpose have been described In the literature, a careful
study of some of these methods was required. In particular, the
Isolation procedure we required had to be simple and offer
quantitative recovery of all the major metabolites.

In addition,

we had to find suitable der I vat I sat I on procedures which were
chemically simple and convenient and which were mild enough so
that back exchange of deuterium with protons was not possible.
Also, we had to ensure that the mass spectra of these derivatives
contained suitable high Intensity fragment Ions containing the
deuterium label, so that measurement of Isotoplc abundances
could be achieved with little or no background contribution.
since biological fluids contain many classes of organic
compounds, a certain degree of fractionation Is necessary before
der I vat I sat I on can be effected.

It Is Important that losses

during the Isolation and extraction procedure should be minimal,
since some tyrosine metabolites such as catecholamines are only
present In small amounts.

For the isotatfon of free tyrosine from the urine, fonexchange chromatography was found to be most suitable*

This

type of Isolation procedure Is often the most time-consuming
step.

For this purpose the Ion-exchange procedure of Harris

et.aU®^ was used*

This Involves the acidification of the

urine to pH 2-3, and then passing the solution through a
column of cation exchange resin (Blorad AG 50W-X2, 100-200
mesh, 500 mg wet weight, H*^ form). The column was then washed
with water.

Finally, the amino acid tyrosine was eluted with

aqueous ammonia, and the eluate was dried under vacuum.
residue was then derlvatlsed for GC-MS analysis.

The

This procedure

gave quantitative recovery of tyrosine (> 95%).
For serum free tyrosine analysis, deprotelnlsatlon was
affected by the addition of alcohol so the final concentration
was 80i v/v. The alcoholic supernatant which contained tyrosine
and all the other amino acids was then evaporated to dryness,
and the residue was derlvatlsed for GC-MS analysis.

Since

tyrosine Is not volatile for GC-MS, the problem Is to find
derivatives which have suitable mass fragmentation patterns for
deuterium analysis.

For this purpose, the N-neopentylldene

derivatives of the amino acid methyl esters were used.®^
compounds were first described by Klyne In

These

This

derIvatI satIon technique was later used by Halpern and

co-workers®^

for the quantitative gas chromatographic determination of serum
phenylalanine In phenylketonuria <PKU).

More recently, Jellum,

Stokke and Eld j a m

extended this derî vat Î sat Ion technique to

a screening program, while Williams and Halpem®^ modified this
procedure further and developed a method by which fifteen of
the Inborn errors of the amino acid metabolism could be
diagnosed by GC analysis of serum and urinary amino acids.
This derIvatIsatIon procedure was used by us for thé determination
of serum and urine tyrosine and the analysis of deuterium contents
of the substrate by GC-MS. The derIvatIsatIon procedure as
described previously Involves the esterlfIcatlon of tyrosine
with thionyl chlorlde-methanol reagent®^ (Equations I and 2)
under reflux for 30 minutes or by heating In a vial (fitted with
a teflon-lined screw cap) at 95®C for 90 minutes.

(I)

OI3OH

+

SOCI2

^

CH3OSOCI

+

HCI

After removal of the excess reagent, the tyrosine methyl ester
hydrochloride (Equation 2) was neutralised with triethyfamine
(TEA) and the free ester was condensed with plvaldehyde to give
the neopentylldene tyrosine methyl ester (Equation 3).

HO - ^ ^
(2)

- CH2 - CH - COOH

CHaOSgCI

NH2
HO - ^ S } • CH2 - CH • COOCH3 + SO2 + HCI
NH2

GH2CH-COOCH3
y
CH-

Figure 7. ia) O-trîmethy i s î î y I N-*neopeniy I î dene tyros I ne
methyl ester
(b) O-methyl N*neopentylidene tyrosine methyl
ester.

HO -

- CH2 • CH - COOCH

I

+

(CH3)3GHO

NHa- HCI

TEA

^

HO - ^ 5 ) "

- CH - COXH3 + H2O
(
N

II

CH - C(CH3)3
The water molecule generated by this reaction was scavenged by
the addition of fnotecular sieve (type 3A).

Finally, the phenolic

hydroxyI group was protected by silylatlon to Increase the
volatility of the tyrosine derivative (Figure 7a). This derivative
chromatographed as a single symmetrical peak on both Aplezon N
and OV-17 columns.

The mass spectrum could be characterised by

fragmentations Involving losses of 57 CC(CH3)3ll and 59 (COOCH3)
from the molecular Ion at m/e 335.

The mass spectrum of this

derivative could also be characterised by a large fragment Ion
at m/e 179 r(CH3)3-Sl-0-C6H5-CH2-D which Is Ideally suited for
the estimation of deuterium content In the aromatic ring (Figure 8a).
When this derlvatlsatlon procedure was applied to deuterated
tyrosine, the percent deuteratlon found by mass fragmentometry
of the fragment Ions at 179, 180 and 181 was found to be I9i.
This low deuterium content on the aromatic ring was obviously
due to back exchange of deuterium with protons during the acidcatalysed esterlfIcatlon step.

This derlvatlsatlon procedure,

therefore, was not suitable for the analysis of deuterated tyrosine

—
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for use In this Investigation.

It seefned obvious that

derIvatIsatIon of deuterated tyrosine for GC-MS required a basecatalysed esterifIcatlon step.
One simple approach to the formation of such volatile
derivatives under these conditions was suggested by the work on
pyroiytic methylatlon of fatty acids and barbiturates.®®

It has

long been known that methyl esters can be formed by heating
tetramethy I ammonium salts of the corresponding acids.®®»®®
This reaction may be carried out at

300^C In the flash heater

of a gas chromatograph®^»®^, but the temperatures required to
affect such conversions are far too high for most applications
since decomposition rather than esterif Icatlon may occur.
More recently, Brochmann-Hansen and Oke®^ have demonstrated
that barbiturates can be methylated quantitatively In the flash
heater of a gas chromatograph using trlmethylanlIInlum hydroxide
(TMAH).

This reagent has already achieved rapid acceptance for

"on column" methylatlon for gas chromatography of barbiturates®**»®^,
cannabis metabolItes®®, dlphenylhydantoln®'*»®^, substituted
phenyl ureas®®, fatty adds®® and aromatic aclds^**.

In view of

the above, Williams and Halpern^°® Investigated the pyrolysls of
the N-neopentylIdene amino acid trlmethylanlI Inlum salts and
found that pyroiytic methylatlon was suitable for the
derIvatIsatIon of most amino acids. The procedure offered
advantages In slmplIclty and convenience over other published
methods, but In addition. It seemed particularly attractive to

us as esteri ficatIon could be effected in a basic medium.
Under these conditions tyrosine was converted to the 0-methyl
neopenty11 dene tyrosine methyl ester (Figure 7b). This
derivative chromatographed as a single symmetrical peak on both
the Aplezon N and the OV-17 columns. The mass spectrum was
characterised by a doublet two mass units apart derived from the
Isobutyl side chain (57 a.m.u.) and the methyl ester function
(59 a.m.u.) and the Cm'*' - C(CH3)3D and CM**" - GCWCHa] at 220 a.m.u.
and 218 a.m.u. respectively.
277 (<

The molecular Ion was small at m/e

while the most Intense peaks above 100 a.m.u. were the

substituted tropy Hum Ion fragment at m/e 121 (H3C-0-C6W5-CH2> and
the loss of this fragment Ion from the molecular Ion Cm"^ - (H3C-0-CgH5-CH2)D
at m/e 156 a.m.u. (Figure 8b). When this was applied to the analysis
of deuterated tyrosine, the percent deuteratlon calculated for the
substituted tropyllum fragment Ions 121, 122 and 123 mass units
(H3C-0-C6H5-CH2) was found to be 80Í dIdeuterated, \9% monodeuterated and IÍ nondeuterated (Figure 6). This method of
derivatisation was therefore employed to establish the extent of
deuteratlon of serum and urine tyrosine in all our further work.
For the analysis and quantitation of the phenolic acids
arising from the metabolism of tyrosine, we used exhaustive
solvent extraction with ethyl acetate and diethyl ether of an
acidified salt-saturated urine sample. This extraction procedure
Is not quantitative for alt organic acids present In the urine
but Is quantitative for the aromatic acids (> 95% recovery).

Ar-C004j

Ar-COOH

Ph

(I)

(U)

Ph -N-iCHj)^

ArOV)

(ffl)
^^CH^-COOCH^

(/I)

(V)
,J
y

-T-CH^COOCH^

R-/
R

CHj

VCH-COOCH3
OCH3
(Vlll)

(VII)

Mil)

R=H;

R'=H

dx)
(x)

R=XH3;R'=0CHJ

Figure 9, Pyrolytlc Methyl at I on of Aromatic Acids.

Since the phenolic acids are not volatile for GG-MS, the
problem of finding a derivative which has suitable mass
fragmentation patterns for deuterium analysis was investigated.
Because of our success with pyrolytic esterificatlon of
tyrosine, we Investigated the possibility of using this technique
for the esterif Icatlon of the phenolic acids. This der I vat I sat ion
of the aromatic acids for gas chromatography Involves the
titration of the acids (I) with trimethylaniIInlum hydroxide
to form the salt (I!) (Figure 9). Pyrolysis of the salt (ID
In the Injector port of the GC yields dimethylani I Ine (III) and
the methyl ester derivative (IV) which can be separated by
GC (Table 3). The trimethylaniIinlum salt solutions (11) are
quite stable and can be kept for several weeks. Identification
of the GC peaks as methyl ester derivative Is based on retention
time data (Table 3) and on a comparison of their low resolution
mass spectra (Table 4) with spectra obtained from aromatic acid
methyl esters prepared by the classical methods using diazomethane
or boron trlfluorlde-methanol (I4i w/v). The results show
(Figure 9) that phenylacetlc is chromatographed as its methyl ester
(V), that a phenolic acid is converted to the 0-methyl methyl
ester derivative (VI), and the ring nitrogen of Indole (VII) and
the o-hydroxyl groups of phenyl lactic acid (VIM), 4-hydroxyphenyl
lactic acid (IX) and 4-hydroxy-3-methoxymandel Ic acid (X) are also
methylated.
The homogeneity of the GC peaks In the chromatograms were

Table 3.

GC Retention Data* for Aromatic Acids

Aromatic Acid

Structure of v o l a t i l e derivative

Phenyl a c e t i c a c i d

8.9

135

Phenyl l a c t i c acid

CeHs-^CHz-coocHa
C6H5-CH(0CH3)-C00CH3

Ì2.9

167

4-Hydroxyphenylacetic acid

CHaO-CeHH-CHa-coocHa

14.0

176

4-Hydroxyph6nyllactic acid

CHaO-CgHij-CH ( OCH 3 ) -COOCH 3

17.2

201

2,5-DIhydroxyphenylacetic acid

2,5-(CH30)2-C6H3-CH2-C0XH3

17.3

202

4-Hyd roxy-3-methoxypheny1acet1c acId

17.4

203

4-Hydroxy->3-methoxymandel I c acid

3 , 4 - (CHaO) 2-C6H3-CH2-COOCH3
3,4-(CH30)2-C6H3-CH(OCH3)-COOCH3

19.4

219

5-Hydroxylndoleacetlc acid

VII

23.6

252

•

Chromatographed Isothermaily for I min a t 80® and then programmed at 8®/mln.

Retention
time (min)

Temperature
(OC)

id

Table 4.

Mass Spectral Fragments Suitable for the Identification of Urinary Aromatic
Acid Derivatives
GC instrument parameters were as specified in Table 3. Carrier gas, helium,
25 ml/min; Bieman separator temperature, 250O; ionizing energy, 70 eV;
current, 100 yA; scan time, 6 sec between m/e 50 to 600.

Derivative

CgHg-CHg-COOCHa
C6H5-CH2-CH(0CH3)-C00CH3

m/e value of ion
M*

(M-COOCHg)

150(50%)

91(100%)

-

135(100%)

CHsO-CgH^-CHz-COOCHa

180(16%)

CHaO-CgH^-CHiOCHa)-C00CH3

224(1%)

2,5-(CH30)2-C6H3-CH2-C00CH3

210(26%)

151(74%)

3,4-(CH30)2-C6H3-CH2-C00CH3

210(26%)

151(100%)

3,4-(CH30)2-C6H3-CH(0CH3)-C00CH3

240(2%)

181(100%)

VII

233(15%)

174(100%)

*

Molecular Ion

OTHERS

(M-CH30H)162 (60%)
(C6H5-CH2)91 (75%)

121(100%)
-

(CH30-C6H^-CH2)121 (100%)
(CH30-C6H4-CH2)121 (100%)

10

15

20

25x10 mmoL
CONCENTRATION

Figure iO. Calibration Curves for Phenylacetic Acid <•),
p-hydroxypheny I acetic acid (X), and 4-hydroxy-3-inethoxyphenylacetic acid («) derivatives.

conftrmed with a fast scanning mass spectrometer, and the linear
relationship between the acid concentration and peak height was
established for phenylacetic acid, p-hydroxyphenylacetic acid
and 4-hydroxy-3-methoxy phenylacetic acid (Figure 10). The
mass spectra of these derivatives were characterised by the
presence of a molecular Ion CM^D and the large Intensity Ions
(M"*" - 59) due to the loss of the COOCH3 function. The value
of this derIvatIsatIon procedure for the analysis of biological
fluids was established when this technique was app I led to the
analysis of urine samples from selected patients with known
metabolic disorders.

The resulting characteristic urinary

profiles obtained by this pyrolytlc method (Figure II) were
compared with the urinary profiles obtained by the standard
sllylatlon method (Figure 12).
The simplicity of the "on column" methylatlon procedure
adds significantly to the potential of GC-MS as an Identification
tool In clinical studies of metabolic disorders.

Unfortunately,

the der I vat I sat I on of p-hydroxypheny I pyruvic a d d (pHPPA) was
not possible by this route, as this acid was oxidised rapidly
In the basic TMAH solutions.

Although the derivative of

homogentlslc acid (HGA) was formed. It underwent rapid oxidation.
Several attempts were made to prepare the methyl esters by the
TMAH route of the 2, 4, dlnltrophenylhydrazine (DNP), or the
hydroxyI amine and methoxylamlne of pHPPA, but In all cases, more
than one product was obtained on GC analysis. We then examined
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Figure 12. (a) Urine aromatic acids from a patient with homogentlsic aciduria <TMS system). 1 • 2, 9
01hydroxyphenyIacetIc acid. <b) Urine aromatic a d d s from a patient with carcinoid syndrome (TMS
system). I « 5-Hydroxylndoleacetlc acid, (c) Urine aromatic acids from a tyrosinosis patient
(TMS system>. I - Phenyl lactic acid; 2 • 4-hydroxyphenyl lactic acid« Cd) Urine aromatic acftf fra»
a patient with neuroblastoma <TMS system). I • 4-Hydroxy-3-methoxypheny I acetic acid; 2 • 4-hydrOKy»
^Haethoxymandellc acid, (e) Urine aromatic acids from a phenylketonuric patient (TMS system).
I » Phenyfacetic acid; 2 « phenyl tactic acid.

the possfbility of carrying out the "pyrolytic" methylatfon at
tower temperatures.

In particular the reaction temperature

was controlled by carrying out the conversion In a high boiling
solvent prior to GC. This was readily achieved with the simple
phenolic acids using toluene as the solvent. Attempts to
prepare volatile derivative of pHPPA by this route were again
unsuccessful.

On the other hand. It was obvious that this

conversion reaction In refluxlng Inert solvent may have
preparative value.
Addenum).

So this Idea was pursued further (see

Because of the failure to produce volatile

derivative for pHPPA, which is the key metabolite In this
study, these derivati satIon procedures were obviously not suitable
for this particular Investigation.
Methylatlon with dlazomethane as a derivatisatIon procedure
for the phenolic acids was not considered suitable since the
rate of methylatlon of phenolic hydroxy I varied greatly with the
structure of the phenolic acld.^®

Although It could be possible

to attempt conversion of all the phenolic hydroxy I groups to
their methyl ether derivatives, this reaction Is not quantitative
for all phenolic groups.

An advantage of the trlmethyl

sllylatlon approach to form volatile derivatives over methylatlon
Is that the problem of a variable methyl ether formation does not
arise.

So, the sllyl derivatives of the phenolic acids were

examined for their suitability for this Investigation. Although
the sllyl derivatives have been reported to be unstable^®^ as
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they readily decompose In the presence of even traces of
moisture, this problem could be overcome If care and attention
was exercised In the preparation of these derivatives; thus.
It was particularly important to remove even traces of moisture
from the samples prior to derfvatlsatlon.

The derlvatlsation of

the phenolic acids were best achieved by the addition of N, 0,
bis (trlmethylsllyl) trifluoroacetamlde (BSTFA) to the dried
urinary extract. This reaction Involves the conversion of the
hydroxyl and carboxyl groups of p-hydroxyphenyIacetic acid (pHPAA)
to the dl-trlmethylsllyl (TMS) derivative (Figure 13a). Similarly,
the alcoholic hydroxyl group of p-hydroxyphenyI lactic acid (pHPLA)
Is also silylated under these conditions (Figure 15b), and the
keto group of p-hydroxyphenylpyruvlc acid (pHPPA) enollses and
Is also si lylated (Figure 13c). The mass spectra of the sllyl
derivatives (a) and (b) are characterised by the presence of
a large fragment Ion at m/e 179 C(Oi3)3-Sl-0-C6H5-CH2-D which
Is Ideally suited for the estimation of the deuterium content
In the aromatic ring, while the large fragment Ion at m/e 325
for (c) is the best fragment ion for the estimation of deuterium
content In (c).
Catecholamines are also formed from the metabolism of
tyrosine In the body. The Isolation and derlvatlsation of
these biogenic amines for deuterium content was also Investigated.
The urinary catecholamines are only present In minute amounts in
normal urinep^®^ and these metabolites must be immediately

protected from oxidation by the addition of antl-oxidants such
as ascorbic acid, mercapto-ethanol, sodium hypophosphlte or
ethylene-diamine tetraacetlc acid (EDTA) to the fresh urines.
Because only small amounts are present, the catecholamines must
be Isolated and concentrated Into a relatively pure extract
before derlvatlsatlon can be attempted.

The alumina adsorption

procedure first described by Shaw In 1938^®^ was Investigated
and was shown to be a simple and fairly specific method of
extracting these compounds from biological materials.

Using

the modification of Lund^®**, we adsorbed the catecholamines
on alumina oxide at pH 8.5 and subsequent elutlon of these
compounds with dilute acid.

Alternative routes such as

adsorption on cation-exchange resins^®^"^®®, were found to be
more time consuming and less efficient than Lund's procedure
which gave us recoveries of catecholamines In excess of 85i.
Currently, these compounds are almost exclusively assayed
for by spectrof Iuorometric t e c h n i q u e s b u t

these

methods lack the specificity and are prone to numerous errors
due to the presence of Interfering, fluorescing and quenching
substances.

The application of GC to the analysis of

catecholamines has had limited success.

Most of the published

work has been with standards, but several GC methods for the
separation and estimation of the catecholamines from biological
materials have been descrlbed^^^"^^^.

Derivatives which have

been used with some success Include the acetyl^^^ and

pentafluoroproplonyl^^'*»^^® derivatives and Capet fa and Hornlng^^^
separated acetone and cyclobutanone condensation products of the
trlmethylsllyl ether derivatives of the physiological amines and
confirmed the structure of the condensation products by GC-MS.
Acetone condensation products were also employed by Beckett and
Wllklnson^^^ In a study of the gas chromatographic separation
of ephedrlne and related amines.

Sen and McGreer^^® prepared

trlmethylsllyl derivatives of these compounds and reported
that all the phenolic and hydroxyl groups were converted to
the IMS ethers and that the reagent hexamethyldlsHazane (HMDS)
also reacted with the amino group to form the N-TMS derivatives.
The sllylatlon of the primary amino group (but not the secondary
amino groups) by HMDS was also documented by Capel la and Hornlng^^^
using (5C-MS. The formation of the TMS derivatives of catecholamines
of undefined structure was also described by Llndstedt.^^^

However,

none of the procedures were entirely satisfactory and thus Horning
et.al.^^^ re-1 n vest I gated the problem of derivative formation with
N-trlmethylsl lyl Imidazole and bis (trlmethylsl lyl) acetamlde as
the sllylatlng agents.

He showed that with N-trlmethylsllyl

Imidazole, all hydroxyl groups were converted to N,N dl (trlmethyl
silyl) amines and N-methyIamIno groups were not sllylated under
these conditions.

More recently, derivatives for catecholamines

suitable for electron capture detection have been developed by
reacting the polyfunctlonal amines with pentafluoroproplonic
a n h y d r i d e . N a r a s l m h a c h a r l and Vouros^^^»^^** recently

(b)

(d) 1

(e)

Ffgure 14, Gas chromatographs of N-trif IuoroacetyI 0-tr iinethyl sf I yI
derivatives of dopamine (I), Noradrenaline (2), Adrenaline (3)r and
Oepa (4)«
(a) Standard solution of catecholamines,
(b) Catecholamines from a normal urine,
(c) Catecholamines from a patient with phaeochromocytotna.
(d) Catecholamines from a patient with neuroblastoma.

described a fairly simple GC-MS technique for the separation and
Identification of some biologically Important amines as their
Isothlocyanate (NCS) derivatives.

In this case the derivative

formation was based on the reaction of a primary amine with
carbon disulphlde.

Finally, Greer, Sprlngle and Wl11lams^^^

described a procedure for the der I vat I sat I on of normetanephrlne
and metanephrlne which uses trlfluoroacetylatlon of the amino
group and a methylatlon step for the alcoholic hydroxy I group
of these compounds. The derivatives chromatographed as single
peaks on GC but no mass spectrometric examination of these
derivatives were made.

For our purposes the last approach

was shown to be the most suitable for the formation of volatile
derivatives of catecholamines. We found it necessary to add
an extra BSTFA derIvatI satIon step to Greer's procedure^^^
to protect the phenolic hydroxyl groups of our compounds. These
N-TFA, 0-TMS derivatives chromatographed as single symmetrical
peaks on OV-225 column (Figure 14a) but dopamine and
noradrenaline had the same retention time on both the OV-17 and
Apiezon N columns. The mass spectra of these derivatives confirmed
their structure (Figure 15). These derivatives were found to be
suitable for our mass fragmentoroetry experiments as they all possess
an abundant Ion which Incorporates the aromatic ring. The mass
spectra of both dopa and dopamine contained an abundant Ion at
267 a.m.u. while those of adrenaline and noradrenaline were
characterised by the presence of an abundant ion at 297 a.m.u.
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CONCENTRATION
Figure 16. Calibration Curves for (•) dopamine and (0) noradrenaline as the N-TFA 0-TMS derivatives.

(Figure 15). A linear relationship between the amine œncentratlon
and peak height could be established for dopamine and noradrenaline
(Figure 16).
The value of this derlvatisation procedure was established
when this technique was applied to the analysis of urine samples
from selected patients with known metabolic disturbances such
as phaeochromocytoma and neuroblastoma (Figure 14c and d),
compared to the catecholamines present in normal urines (Figure
14b).
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17. COMPOUNDS AND RESPECTIVE ION FRAGMENTS ON WHICH DEUTERIUM
MEASUREMENTS

WERE MADE

The clinical runs with deuterated tyrosine on the two
patients and a control subject were carried out with a tyrosine
load of 829 pmol/kg body weight. A second run was subsequently
carried out with a reduced load of 276 |imol/kg body weight. The
experiments were done by collecting urine samples from the
patients over a forty-eight hours period after the tyrosine
load was Ingested.

Blood was collected at random times during

the loading experiment for serum tyrosine analysis.
Deuterium analysis were carried out on serum and urinary
tyrosine, urinary phenolic acids and the catecholamines.

The

derivatives prepared for this purpose were the O-^nethyl ether
of the neopenty 11 dene tyrosine methyl ester, the TMS derivatives
of pHPAA, pHPLA and pHPPA and the N-trlfluoroacetyl 0-trlmethytsllyI
(N-TFA, 0-TMS) derivatives of dopamine, adrenaline and noradrenaline.
Precise measurement of the deuterium content of the compounds
studied was achieved by GC-mass fragmentometry procedure In which
the Ion of Interest was scanned repeatedly for the determination
of deuterium Incorporation.
121-123 for tyrosine;

The Ions examined In this way were

179-181 for both pHPAA and pHPLA; 325-327

for pHPPA; 267 and 268 for dopamine and dopa and 297 and 298
Ions for both adrenaline and noradrenalIne (Figure 17).

Initially

short manual scans across a limited mass range were taken, and
peak heights were measured by hand.

Later on, the computer

operated quadrupole mass spectrometer was programmed to operate
In a mass fragmentometry mode with settings optimised for Isotope

measurement.

With the rapid automatic scan. It was possible

to accumulate many measurements of relative peak heights from
which mean values were calculated.

When measured In this

fashion, the precision of Isotope measurement as judged by
the abundance of^^^ Xe relative to^^^ Xe was found to vary
by ± 0.4$ of the reported value^^^.

There Is no doubt that

variations In the sample pressure In the source of the mass
spectrometer during GC-MS are responsible for some loss In
precision.

The Introduction of the computer operated mode

which greatly f a d IItated data collection, permitted the
tyrosine load to be reduced from 829 pmol/kg body weight to
276 pmol/kg body weight without any loss In precision In the
deuterium measur^ent of a peak.

The computer method reduced

the error of the measurement of the mean deuterium content of
a metabolite by 1/3.
The first series of experiments were performed on the two
patients before any dietary treatment was given and on the
normal control using an oral load of 829 ymol of tyroslne/kg
body weight (preliminary reports have been publlshed^^^*"^^®).
The deuterated tyrosine substrate used consisted of 80$ dldeuterated species (Da-tyrosIne), 19$ mono-deuterated species
and 1$ unlabel led tyrosine.

This represented a load of 663 pmol

of dl-deuterated tyrosine (D2-tyroslne)/kg body weight.

The

study of P.R. was performed first and was continued for only
24 hours.

After examining the results of this experiment, all

other studies were continued for 48 hours.

As shown In Tables

5 and 6, forty-eight hours after the load was taken the
deuterium content of the urinary metabolites had almost
returned to zero.
The urinary output of free tyramlne and conjugated tyramlne
were determined but the amounts In I ml samples of urine from
both patients and the normal were below our limits of detection
by GC-MS.

Conjugated tyrosine (N-acetyl tyrosine) was

determined In the urines of the patients and the normal In
the first series of experiments and were found to be Increased
In both patients.

The urinary output of deuterated conjugated

tyrosine was not determined because the relatively small
production of this metabolite would account for less than 5%
of the total recovery of deuterated metabolites In the urine.
The urinary output of catecholamines were also determined,
but because of the relatively sma11 production of these metabolites.
It was only possible to determine the proportion of the deuterium
label In these compounds, but not the absolute amounts.

Because

of the lower concentration of adrenaline and dopa In urine, the
concentration of these metabolites were below our limit of
detection.

The relatively smalI amounts of these metabolites

present In the urine, however, would only affect the deuterium
recovery by less than 0. IJf, although In patient J.L. the urinary
excretion of dopa and dopamine has been reported to be Increased.®^
The increased excretion of these metabolites Is suggestive of a

TABLE 5. CONTROL DEUTERATED TYROSINE LOAD
( 6 6 3 U M O U S D 2 - T Y R O S I N E / K G BODY WEIGHT) •
tfflllfC

2

{

i
e

S

i

0
1
2

84
40
171
150
130
400
«00
221
901^

3-5
0.7$
2.82
2.97
2.34
1.82
2.21
3.31
3.S0
11.39

Sorwi
0
1 2.9
2 7.9

f

OCUTERIUH CONTENT
(f Oi-speclttt)

TOTAL AMOUNT D.-SPCCIES
EXCRETED, (unol 0,netabolfte/kq body
weight

TOTAL AMOUNT D.METABOIITE (mumol
Oj-Metibome/kg
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uHn«)

TOTAL AMOUNT 0,METABOLITE
02-inetabo1Ue/k9
body welght/mnol
Creat(nlnt)

t i

I

>

£ I
J i
t

0
2.2S
6.0
1 12.0
4 15.0
S 18.0
6 23.0
7 29.0
8 48.0
TOTAL

TOTAL AMOUNT
(iMl/ks IxMbr Ml9llt)

Ii IfP
0.04
0.03
0.65
0.55
0.38
0.31
0.29
0.35
1.09
3.69

0.02
0.05
0.14
0.09
0.14
0.07
0.13
0.10
0.63
1.37

t

!
0.04
0.08
1.57
2.71
0.02
0.36
0.25
0.39
0.99
7.21

<0.01
0.12
0.09
0.04
<0.01
<0.01
<0.01
<0.01
<0.01
0.2

>1 tyro$tn»/i

NO
NO
NO
NO
NO
ND
ND
ND
NO

0
*

42.89
23.06
8.29
S.18
3.21
1.79
1.90

I

0 0 .
0
•
0.01 0.01 NO 0.02
16.26 5.99 NO
0.28 0.74 0.02 NO 1.04
46.86 21.10 NO
43.29 26.71 NO
0.13 1.17 0.01 NO 1.31
0.03 0.32 <0.01 ND 0.35
39.49 27.90 NO
0.02 0.10 <0.01 ND 0.12
27.24 8.47 NO
0.01 0.06 <0.01 ND 0.07
23.82 5.12 ND
0.01 0.05 <0.01 ND 0.06
12.87 1.09 NO
0.02 0.03 <0.01 ND 0.05
0.00
ND
2.54
3.02
0.50 3.48 0.04

1.6
0.9
0.2
0.05
0.03
0.05
0.02

0.25
4.3
7.8
2.5
0.3
0.15
0.23
0.03

0.25
0.12
0.07
<0.01
<0.01
<0.01
<0.01
0.01

ND
NO
ND
NO
ND
NO
NO
NO

*

0.004
0.09 0.25
0.06 0.50
0.02 0.18
0.01 0.05
<0.01 0.02
<0.01 0.01
<0.01 <0.01

i 0,*tyro»iw

0.07
0.39

0
39.29
29.62

0.22

Mtufflcltrtt twpl«
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1 f
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0
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*
T H

0.004
0.007
0.004
<0.01
<0.01
<0.01
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NO
ND
ND
ND
•ND
ND
ND
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defect In catecholamine metabolism In patient J.L, and this
may explain the pronounced tremor evident in this patient.

It

would seem most likely that such an abnormality (resulting in
an increased urinary output of only 1.6 pmol/day of dopa and
dopamine) Is a consequence of, rather than the reason for, the
primary defect In tyrosine oxidation.
In this series of experiments with deuterated tyrosine
loads, very little of pHPLA, pHPAA and tyrosine were excreted
in the urine of the control, although the last two metabolites
were excreted In larger amounts (Table 5). There was no
detectable pHPPA in the urine of the control. The deuterated
metabolite excreted in large amounts In the urine was pHPAA and
this metabolite accounted for the major deuterated metabolites
in the urine.

In the 48 hours period after the oral load, only

0^46% of the deuterated load was recovered in the urine and
most of the label was excreted In the first 24 hours.
In a similar experiment with J.L. on an oral load of 663
pmol of deuterated tyroslne/kg body weight, large amounts of
tyrosine, pHPAA, pHPLA and pHPPA were excreted In the urine.
By far the major metabolites excreted by this patient were pHPLA
and pHPPA which were excreted some 7-8 times more than that of
tyrosine and pHPAA. The total amount of deuterated metabolites
excreted 48 hours after the load amounted to I6.7Í of the load;
the major contribution came from pHPLA and pHPPA (88Í of the
total deuterated metabolites excreted) (Table 6). Patient J.L.
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0.21 l . l t
0.74 4.68
0.63 10.10
1.00 29.99
2.S9 44.89

TOTAL AMOUNT 02-METAB0LITE TOTAL MOUNT 02-NETAB0LITE
(iiffol O-HMtabolftt/
(«yiMl OjHMUbolUt/k« body
kg
body wflght/nnol
«ftlght/Hl urini)
Crfitlnlnt)

i

1.42 0.91 3.24 1.19
19.29 10.31 39.00 11.99
19.32 . 9.17 40.00 4.09
r.32 8.44 40.14 2.00

Ricovfry of Oj^plMnolk «oltty •

• 9.791

0.21
1.28
9.19
1.81

0.08
0.81
1.27
t.09

0.48
2.77
8.80
9.94

0.18
0.9i
0.84
0,90

o\

O

TABLE 8.

RECOVERY OF DEUTERATED METABOLITES IN THE ÜRINE FROM PATIENTS J.L. AND P.R. AND
A NORMAL SUBJECT FOLLOWING A DEUTERATED TYROSINE ORAL LOAD.
•

SUBJECT
J.L.

P.R.

NORMAL

1.37

1.52

0.07

663

663

663

(0-48 HOURS)

(0-24 HOURS)

(0-48 HOURS)

D2 - TYROSINE

6.32

7.31

0.50

D2 - PHPAA

6.78

5.92

2.48

D2 - PHPLA

51.19

29.04

0.04

D2 - PHPPA

-46,60

2.58

NOT DETECTED

TOTAL

ilU.ö3

44.85

3.02

(0-2^ HOURS)

11.7

6.8

0.44

(0-48 HOURS)

16.7

-

0.46

INITIAL SERUM TYROSINE CONCENTRATION
(MMOL/1)
ORAL D2 - TYROSINE LOAD
(|JMOL/KG BODY WEIGHT)
RECOVERED IN URINE
(PMOL/KG BODY WEIGHT)

^

A I "

TOTAL AS PERCENTAGE OF INGESTED

continued to excrete substantial amounts of the label In the
second 24 hours.
In a similar experiment with P.R, on an oral load of 663
pmol of D2-tyroslne/kg body weight, elevated levels of tyrosine,
pHPAA, pHPLA and pHPPA were excreted In the urine. The major
metabolite excreted was pHPLA while pHPAA and pHPPA were
excreted In smaller amounts. The total recovery of deuterated
metabolites in the 24 hour period after the load was 6.76i
(Table 7).

It was unfortunate that the study on this patient

ceased at 24 hours» because her excretion of deuterated
metabolites at 24 hours was still increasing.
The total recovery of the two deuterium labels fn the
phenolic ring of tyrosine and tyrosine metabolites (referred to
as D2-phenollc moiety) In the urine of the three subjects
following the Initial series of experiments with 663 pmol of
02»tyrosine/kg body weight are sufnmarlsed fn Table 8. Very
little of the D2-phenollc moiety was recovered In the urine of
the patients, particularly J.L. Assuming melanin, thyroxine
production and protein biosynthesis are roughly equivalent In
the three subjects, then the Increased recovery of the D2-phenollc
moiety with the patients must reflect an Impaired rate of oxidation
of tyrosine.
The total serum tyrosine and the concentration of D2-tyroslne
In the serum were both measured. The total tyrosine level rose
to very high levels In patient P.R. and were still not back to
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TABLE 9. J.l. DEUTERATED TYROSINE LOAD
(221 JJHOLES D a - T Y R O S i N E / K G BODY W E I G H T )

wmc

^
TOTAL /MOUNT
C|H9l/k9 b o ^ M i g h t )

•

KUTEftlUN CONTENT
( I 0|-ipMtM)

1

1.58

18«

1.32

f
1

<.$0

208

O.N

<

1t.2S

31«
307

1.2?
1.88

f
i

tS.7S
26.2S

46»

3.81

101

1

28. M

12S

II.M

f
10

«s.;f

11
010

47.IS

108

0.1«

TOTAL
StnM
0
1
t
1

N

I
I

1.18
2.2S
1.88
1.38

1.81
2.28

13.83
10.82

8.31
6.32

2.37
3.22

21.33

17.12
19.57
38.36

0.18

0.87

0.18

0.61

0.98

3.41

0.93

1.80

2.28

2 1 . 2 7 10.35

0.45

1.11
1.03

34.56 10.91

o:i8

5.29
5.61

2.57

15.10
24.91

0.57
8.42

36.88 11.85
24.28 15.54

0.12

0.45

4.36

0.11
0.14

0.30

2.27

1.45

0.33

2.45

0.22

3.21

0.S7

0.72

3.27

24.8

24.76

17.11

0.34

0.80

8.72
10.(1

18.4

16.54
13.34

16.97
12. &l

14.37
9.28

0.48

1.77

0.12

0.32

17.15
2.45

5.51
1.57

4.46

1.19

2.81
3.81
3.17

11.02
8.25

10.61

9.20

0.13

0.31

2.30

0.21

2.95

1.04

2.48

18.40

1.68

6.81
6.42

«.0«
4.90

0.07

0.21

0.23
0.36

1.09
5.07

0.47

11.98
7.38

8.1«
0.8«

0.11

O.M

0.43

0.30

t.83
0.78

0.08
0.04

0.07

4.82

4.11

0.04

0.05

0.32

0.43

0.30

0.40

S.00

O.lf

0.07

0.08

0.99
0.87

0.11

4.38

0.59
0.02

1.86
8.21

0.77

.4.56

t.<4

5.70

50.07

18.10

16.87

13.1

21.64

2.23

13.1

1.10

0.«4

8,1«

MS

2.73
8.8«

11.78
83.84

7.73
11.77

11.1
8.«

0.48

0.94

7.29

0.51

14,18

36.07

»41.84

126.79

0.0

M.OS
I4.$7

0.08

1.15

0.90

20.38

0.11
•.40

1.29
4.18

0.24

0.S7

2.39

0

6.18
15.43

0.11

2.81

S2.31

1.29
4.33

3.7«
13.83
19.08

1.01

0.40

0.59
2.74

8.47
29.38
31.52
27.62

1.08

0.31

1.74

9.63

0.94

0

!

31.88

10.73
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I

I

8.9

t.83
0.88

11 t]froi(f|t/1
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25.4
28.7

38.40
101.06
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TOTAL A ^ T
METABOLITE { y m i D . M e t i l i U t P«r k« b M y
wtiht/^ol CrttHfHw)

t

i l 'i Lr
Ml I II

•

TOTAL AMOUNT 0 . METABOLITE ( a u n o r o , .
H « t « b « 1 1 U p t r k9 bSdy
«tight/«! w l M )

TOTAL AHOUNT 0.-SPC€tES
EXCKETEO (tiMil 0 « - N c t a b o 1 l U /
k9 body wftfsht)

30.30

0.24
0.87
3.35

8.55
11.28

74.81

.i.1 O^-tymlM/l
0
O.ltt
0.17
0.00

Itecovtry e f O ^ - i H i i M l f c M i t t j r •

• 13.711

1.77
1.40

0.04

preload levels 7 days later (Figure 18c).

The rises observed

In J.L. and In the control were similar and more transient
(Figures 18b and I8d).

The initial rate of appearance of D2-

tyrosine In the serum was very similar In all three subjects,
but both patients differed from the control in that the D2tyrosine continued to rise up to 8 hours after the load,
presumably reflecting very slow intestinal absorption (Figures
18a and 18b), whilst the level of D2-tyrosine In the control
continued to fai I through this period.
A remarkable difference in the tyrosine metabolism of the
two patients only became apparent after a second series of
experiments, with a reduced load of deuterated tyrosine (221
pmol/kg body weight) was carried out.

These experiments were

run after the patients' serum tyrosine concentration had been
lowered through the restriction of dietary Intake of phenylalanine
and tyrosine.

The results with J.L. In this second series of

experiments (Table 9) were very similar to that produced In the
first experiment (Table 6).

The total recovery of D^-phenollc

moiety 48 hours after the oral load was Ingested was 33.7IÌ.

In

both experiments with J.L. significant amounts of the three
deuterated p-hydroxyphenolIc acids were recovered In the urine,
with pHPLA and pHPPA In both experiments accounting for 89Ì of
the total urinary D2-phenollc moiety.
Patient P.R. behaved In a different fashion in the two
loading experiments.

In the first experiment with P.R. (Table 7)

TABLE 1 0 .

P . R , DEUTFPATfp TYRQSIHf LOAP

( 2 2 1 IJMOLES D 2 - T Y R O S I N E / K G BODY WEIGHT)

(mtNC

TOTAL AMOiiNT (|«o1/kf OCUTERIUN GONTENT
bodyMflght)
»¿-tpeclts)

TOTAL AMOUNT D.-$FECIE$
EXCRETED (pmol 0.MetabolUe/ka body
weight)

TOTAL AMOUNT D.NETABOLITE (fflM^t
D2-Riet«betUe/k9
body wel9ht/iit
urine)

TOTAL AMOUNT 0,KETABOLITE (umSI
Oj-Metabollte/kg
body welght/mmol
Creitlnint)

1
i

«

1 1 ri I i

s

1

3.25

2
3

4.33
7.00
8.00
9.8

4

S
8

lO.S

7 21.S
8 24.7
9

-r

£ Z

27.25

10 29.25
11 46.0
tOTAL

Seruw

49 0.39
24 0.11
79 0.13
39 0.09
37 0.15
14 0.05
1S1 1.01
28 0.35
27 0.29
23 0.18
143 0.40

1.12 0.85 NO NO
0.48 0.24 NO NO
0.89 0.29 NO NO
0.47 0.20 NO NO
0.72 0.34 NO NO
0.27 0.11 NO NO
2.19 1.59 NO NO
0.34 0.65 NO NO
0.61 0.99 NO NO
0.46 0.4D NO NO
2.33 0.98 NO NO
9.88 8.64

i m i tyros 1nt/1

I

I
9.99 7.49 NO NO
15.03 12.72 NO NO
11.76 15.14 NO NO
9.91 15.23 NO NO
9.07
8.49
8.17
3.57

I

I I
13.14 NO
11.07 NO
6.90 NO
1.42 NO

NO
NO
NO
NO

0.11 0.06 NO NO 0.17
0.07 0.03 ND NO 0.10
0.10 0.04 NO NO 0.14
0.05 0.03 ND NO 0.08
0.07 0.04 ND NO 0.11
0.02 0.01 ND NO 0.03
0.11 0.11 NO NO 0.22
0.01 0.02 ND NO 0.03

1.29

2.63 NO NO

0.01

0.89

2.77 NO NO

<0.01

0.09

1.97 NO NO

<0.01 0.02 NO NO 0.02
0.55 0.40
0.95

% Og'tyros<nt

0.03 ND
0.01

NO 0.04
NO NO 0.01

0

0.81
0.81

80.18

0.16

4

18.8$

0.18

14

0.71

8.IS

0.04

t4 I f I

0.(3

0

0

t

RO M l dtlfctN Ity 8C«NS In «r^tiile acltf txtnct «f 1 «1 u H m

2.24

1.22 NO ND

0.282 0.154

2.92

1.25 NO NO

0.636 0.272

1.27 0.51 NO ND
1.28 0.77 NO NO
1.89 1.08 ND NO
1.43 0.71

NO NO

0.73 0.73 NO MO
0.36 0.71 NO NO
0.37 1.11 ND NO
<0.40 0.43 NO NO
<0.07 0.14 NO NO

NO NO

ND NO
0.769 0.308 ND NO
0.556 0.333 ND NO
0.467 0.267 NO NO
0.400 0.200 ND NO
0.109

0.109 ND NO
0.029 0.020 ND NO
0.034 0.103 NO NO
<0.063 0.063 NO NO
<0.025 0.050 NO NO

m o 1 Oy'tyroilnt/i

0.31

0

If

I

0
Rtcovfiy of 0^-|MiMOl1e Mltly • ^

• 0.4»

TABLE 1 1 .

RECOVERY OF DEÜTERATEO METABOLITES IN THE ÜRINE FROM PATIENTS J.L. AND P.R.
FOLLOWING A REDUCED DEUTERATED TYROSINE ORAL LOAD.

SUBJECT

INITIAL SERUM TYROSINE CONCENTRATION

J.L.

P.R.

0.33

0.33

(MMOL/1)
ORAL DJ - TYROSINE LOAD {;LIMOL/KG BODY WEIGHT)

221

•

221

(0-18 HOURS)

(0-18 HOURS)

2.61

0.55

PHPAA

5.70

0.10

DG - PHPU^

50.07

NOT DETECTED

DA - PHPPA

16.10

NOT DETECTED

TOTAL

71.51

0.95

(0-21 HOURS)

26.50

0.10

(0-18 HOURS)

33.71

0.13

RECOVERED IN URINE (;UMOL/KG BODY WEIGHT)
P2 - TYROSINE
•DA -

TOTAL AS PERCENTAGE OF INGESTED

O\
•vj

significant amounts of the three p-hydroxyphenolic acids were
recovered In the urine and urinary pHPLA and pHPPA accounted for
10% of the total D2-phenollc moiety.

In the second experiment

with P.R. neither pHPLA nor pHPPA could be detected In the urine.
The total recovery of D2-phenollc moiety was only 0.43ÍÍ (Table
10).

A summary of the recovery results from the reduced D2-

tyroslne load Is shown In Table II.

Similar results to those

obtained in the second experiment with P.R. were obtained In
the single experiment with the normal subject where neither
pHPLA nor pHPPA could be detected In the urine (Table 5).
A summary of the recovery results from the 5 experiments
with D2-tyroslne Is given in Table 12. (k)mparlsons of the
raw data of recovery of label between the subjects in the two
series of experiments are complicated to some extent by
differences In serum tyrosine pool sizes.

However, when the

data has been transformed by correcting for the Initial serum
tyrosine concentration (Indicating the tyrosine pool), a
significantly greater recovery was obtained In both experiments
with P.R. than with the control subject (Table 12).

This

comparison clearly shows that J.L. metabolised the label almost
equally poorly at high or low serum tyrosine levels.

However,

the disposal of label In P.R. Improved dramatically when the
serum tyrosine level was lowered.
Measurement of the concentration of 02-^tyroslne In the
serum of the patients following the second oral load of D2-tyroslne

TABLE 12.

SUMMARY OF 5 EXPERIMENTS WITH DEUTERATED TYROSINE LOAD:

RECOVERY OF URINARY

DEUTERATEO TYROSINE A N D TYROSINE M E T A B O L I T E S .

SUBJECT

INITIAL S E R U M TYROSINE
CONCENTRATION

NORMAL

P.R.

J.L.
1.37

0.33

1.52

0.33

0.07

663

221

663

221

663

0-18

0-18

0-21

0-18

0-18

110.85

71.51

11.85

0.95

3.02

(MHOL/1)

O R A L DEUTERATED TYROSINE LOAD
(;JMOL/KG BODY W E I G H T )
RECOVERED IN URINEJTIME PERIOD

(HOURS)

T O T A L D J - PHENOLIC M O I E T Y

VO

(;UM0L/KQ B O D Y W E I G H T )
T O T A L DJ - PHENOLIC M O I E T Y

16.72

33.71

6.7

0.13

0.16

22.90

11.12

10.3

0.11

0.03

AS % OF O R A L LOAD
T O T A L DG - PHENOLIC M O I E T Y
CORRECTED +
+

C O R R E C T E D FOR INITIAL S E R U M T Y R O S I N E C O N C E N T R A T I O N A N D C A L C U L A T E D AS

TOTAL RECOVERY
TOTAL ORAL LOAD/INITIAL
SERUM TYROSINE

CONCENTRATION.

Is shown In Figures 18a and 18b and changes In total serum
tyrosine are shown In Figures 18c and I8d.

Patient J . L J s

results followed a similar pattern to the previous study,
although the Increase In serum tyrosine concentration In this
experiment was smaller than the Increase In the Initial
experiment.

In patient P.R. the concentration of serum D2-

tyrosine was constant between 2 to 4 hours after the load was
taken and again the Increase In serum D2-tyroslne In this
experiment was smaller than the Increase In the Initial
experiment.
The most likely explanation for the difference between the
patients and the normal In the increase of serum concentration
of D2-tyroslne following the first oral load of D2-tyroslne
(Figure 18a and b) would seem to be a consequence of the competing
processes of absorption from the intestine and the removal from
the serum via transport Into the tissues and normal oxidation.
Intestinal absorption of amino acids from solution is thought
to be virtually complete within 2-3 hours following ingestlon^^®,
but the very low solubility of tyrosine (4.14 mmol/litre of
water at 40®C) and the high tyrosine load used In this experiment
could significantly prolong the time taken for complete absorption
Thus, it appears likely in this experiment that during at least
the first 8 hours after Ingestion, D2-tyrosine was still being
absorbed from the intestine in all the three subjects.

In the

patients then, the continued Increase In serum D2-tyrosine

(b)

8
16
24
32
HOURS AFTER LOAD

6

16

24

32

40

HOURS AFTER LOAD

Figure 19, Graphs showing the deuterium content In (a) dopamine and (b) noradrenaline from the
deuterated tyrosine loading experiment (663 pmol/kg body weight) In the control (•), patient J.L.
(X) and patient P.R. (0).

48

cx>ncentratIon during the first 8 hours Is likely to be a
reflection of a reduced rate of tyrosine removal from the
serum by the oxidative enzymes In the liver.
Delayed Intestinal absorption of tyrosine Is likely to
be operating In the second series of experiments with the
lower D2-tyroslne load.

Although the oral load was reduced

to 1/3 of that used Initially, the amount used would still
be sufficient to result In a precipitation of tyrosine in
the small Intestine.

Thus, the result for serum concentration

of D2-tyroslne for the first 4 hours following the load In the
second series of experiments with reduced loads would also be
a summation of the competing processes of tyrosine absorption
from the Intestine and Its removal of D2-tyroslne from the
serum.
The deuterium content of the catecholamines which were
determined showed the deuterium labelling of dopamine was
higher In the control than that found In the patients (Figure 19).
This difference must be attributed to the dilution of deuterated
tyrosine with the tyrosine already present In the tissues and
body fluids of the patients.

It was also observed that during

the run of the experiment, the specific labelling of noradrenaline
reflected that of dopamine.

Because of the relatively small amounts

of these metabolites present In the urine of the three subjects,
which would only alter the deuterium recovery by 0.l/f the defect
In the patients would seem to be In the oxidative pathway of

TABLE 13.

INCREASE IN SERUM TYROSINE FOLLOWING TYROSINE LOAD.

SUBJECT

NORMAL

P.R.

P.R.

INITIAL SERUM TYROSINE LEVEL (MMOL)

0.07

1,52

0.33

TYROSINE LOAD (UMOL/KG BODY WEIGHT)

829

829

276

MAXIMUM SERUM TYROSINE

505%

200%

107%

AS % OF INITIAL

^

tyrosine.
The results obtained show that loading rates of 221 ymol of
deuterated tyroslne/kg body weight are adequate for precise
measurement of stable Isotope content of serum and urinary
tyrosine and tyrosine metabolites.

The Initial loading rate

(663 ymol of deuterated tyrosine) Is a gross load producing
In the normal a 5-fold Increase In serum tyrosine concentration.
The second load used In the second series of experiments (221
pmol of D2-^tyroslne) had virtually no effect on the level of
serum tyrosine concentration In patient P.R. and would be
expected to produce a 1-2 fold Increase In serum tyrosine
concentration in the normal (Table 13). This load Is
approximately equal to the load our bodies are subjected to
following a protein meal.

Considered in this light, we assert

that the reaction which we have been following at least with
the reduced tyrosine loading must reflect normal body metabolism.
The results obtained with patient J.L. showed an obvious
impairment in the rate of tyrosine oxidation with high and low
tyrosine concentration (Table 12). This result suggested to
us that the most likely location of the metabolic block in this
patient is at the position of p-hydroxyphenyI pyruvic acid oxidase.
As a consequence of such a block pHPLA and pHPPA would be produced
and excreted In large amounts and the synthesis of tyrosine could
then take place by reversal of tyrosine aminotransferase.

The

elevation In tissue and serum tyrosine concentration so resulting

could lead to an Increased production of conjugated tyrosine
(N-acetyl tyrosine), pHPAA, dopa and dopamine.
In patient P.R. the recovery of deuterated metabolites
In the urine following the reduced load of D2-tyroslne was 6.4Í
of the recovery obtained following the Initial larger load
(Table 12).

This reduced recovery must reflect an Increased

capacity of the oxidising system to oxidise the substrate after
serum tyrosine concentration had been lowered.

We believe that

In this patient this Increase capacity Is due to the removal of
the substrate Inhibition of pHPPA oxidase.

This enzyme has been

shown to be susceptible to substrate Inhibition In vltro^^^»^^^.
In another patient, described by Kennaway and

with

deficient hepatic cytosol tyrosine aminotransferase and the
same skin and eye lesions as P.R. substrate Inhibition of pHPPA
oxidase has been postulated to explain the unexpected accumulation
of the metabolic products of the defective enzyme as well as Its
substrate^^^.

This Inhibition manifests Itself when patient P.R.

Is on a normal diet, and It Is presumably an effect secondary
în nature to the primary biochemical defect. This study confirms
the existence of the phenomenon of substrate Inhibition of pHPPA
oxidase, but It Is most unfortunate that we lack proof of the
basic enzyme defect In patient P.R. The primary metabolic
defect In patient P.R. remains obscure except that It appears
to be distinctly different from that In patient J.L.

The

clinical symptoms In P.R. strongly resemble those of a patient

already described with deffcfent hepatic cytosot tyrosine
aminotransferase^^, thus suggesting a common defect.

There

are, however, some Inconsistencies between the two. Including
the absence of an elevated excretion of p^tyramlne and the
small elevation In excretion of N-acetyl tyrosine In our
patient.

One should not be too surprised by differences In

by-products of accumulating metabolites In different patients
with the same basic metabolic block for genetic heterogeneity
Is great In normal humans and this must cause differences In
the capacity of these minor pathways.

An outstanding feature

of this patient has been the resolution of the clinical symptoms
following restriction of the dietary Intake of tyrosine and
phenylalanine.

We believe that the removal of substrate

Inhibition of pHPPA oxidase, which was operating under conditions
of high serum tyrosine concentration Is responsible for this
effect.
Although the biochemical abnormalities of the patient J.L.
are similar to those seen In hereditary tyroslnaemla, the adult
patient J.L. differed clInlcal ly In that no signs of liver
failure, hepatosplenomegaly or renal tubular dysfunction of the
Fanconl type was evident.
cases reported by Medes^S

The patient closely resembles the
Wadman et.al.^^u^ ^^^

discrepancies In the biochemical data.

^^^

In contrast to the

patient reported here, Medes was unable to detect pHPLA In the
urine except when the patient was given a high tyrosine or high

pHPPA d!et.

La

epecuisfed that Medes patient tias urifque

and that the relative lack of pHPLA In the urine and the
failure to detect tyrosine In the urine during oral loading
with 4 g/day of pHPPA suggested a defect In hepatic tyrosine
aminotransferase, rather than pHPPA oxidase as originally
proposed by Medes.^^

In reviewing Medes data It should be

remembered that In 1932 she was not able to measure serum
tyrosine accurately.

In addition, direct quantitation of

urinary tyrosine and Its oxidative metabolites was not possible.
In view of this. It Is difficult to evaluate the reported
absence of pHPLA and tyrosine from the urine In some of her
metabolic studies^

In her paper, Medes commented that she was

unable to detect tyrosine In the urine unless the urinary
excretion of pHPPA exceeded 3 g/day. This required a dally
tyrosine Intake of at least 5 g/day and for reasonable
Indirect quantitation 10 g/day.

It was not surprising, therefore,

that oral administration of 4 g/day of pHPPA for two days was
not associated with detectable levels of tvroslne In the urine.
The absence of pHPLA may also reflect the Insensltlvlty of the
assay methods available at the time.

If the quantitative

biochemical differences between Medes patient and the patient
J.L. merely reflect differences In methodology then the patient
of M e d e s , t h e patient J.L. and the case reported by Wadman et.al.^^^
are all examples of the same disorder. The high concentration of
pHPPA In the urine In all three cases Indirectly supports Medes
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suggestion of a defect In pHPPA oxidase.
So far as we know, six other patients have been described
In the literature with clinical and/or biochemical features
resembling those of our patlents®^»®^'^^'»"^^^^
biochemical and enzymologlcat analyses have been carried out
only on the patient described by Kennaway and Buist®^ In which
the deficiency of tyrosine aminotransferase was s h o w n . T h e
clinical and biochemical features of the six other patients
are summarised In Table 14. There Is no evidence of liver or
kidney disease In these patients. Mental retardation has been
a prominent feature as have eye and skin lesions. However,
considerable heterogeneity exists In the clinical features and
biochemical findings.

In the light of the conclusions reached

about the defect In the two patients described by us, we feel
It would be unwise, without detailed metabolic and enzymologlcal
evidence to predict the likely locatlon<s) of the metabolic
defects In the other patients.
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ADDENUM
Preparative EsterffIcation of Carboxyllc Acfds via Pyroiytfc
MethylatIon^38
Because of our success with pyrolytlc esterifIcatlon of
tyrosine, we Investigated the possibility of using this technique
for the esterifIcatlon of carboxyllc acids In general.

This Is

based on the thermal decomposition of trimethylani IInlum salts
of carboxyllc acids In an Inert solvent medium at reflux
temperatures.

This new esterifIcatlon method Is thorough and

mild and even sterlcally hindered acids such as (2) In Table
15 are converted cleanly to their methyl esters In excellent
yields (85i).

Other acidic functions, such as the phenolic

hydroxy! are also methylated under the above conditions (3).
Since the reagent, methanollc trimethylaniIInlum hydroxide Is
commercially available, the procedure offers great potential
as a general, single step methylat Ion reaction for carboxyllc
acids and phenols.

R-C^

0

H3C
+

N ^ /—\
HjC- N - f

H3C

0

"3C

TABLE 15,

Ester!ffcation of Carboxyffc Acids by Thermal Decomposition of

their TrImethylanIIInlum Salts,

No.

R-C'
^OH

R-Q
^O-CHs

OH

^ ^

b.p.'

Mass spectra*' (m/e)

l98-20(r

136 (M®), 105 (G^Hj—CG®)

115°/8 torr

178 (M®), 149 H j C - ^ ^ C O

^O-CHj

CHj
CH3
HjC-O

tHj

O-CHj
HjC-C
^OH

HjC-O

-0

121-125/10 torr

166 (M®), 135

165-16r/10 torr

200 (M®)

155-15878 torr

242 (M®)

l^co

HaC-C^
^O-CHs

yKi

^0-CH,
• The purity of the products was confirmed by gipc, using an 8' x 1/8" s.s. column of 5% OV 17 on silanized chromosorb W. Satisfactory analytical data were obtained for all compounds.
** Mass spectral data were recorded on an EAI Quad 300 mass spectrometer.
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GENERAL
Gas lîquîd chromatographic separations were carried out
with a Becker Packard Model 419 gas chrofnatograph (Delft, The
Netherlands) using a quartz tip flame Ionisation detector. The
I tt
columns employed were an 8' x -5- O.D, stainless steel column
o
packed with 5% Silicone OV-17 on acid washed dimethyIdlchlorosIlane
(DMCS) treated chromosorb W(80-I00 mesh);

a 2m x 2,5cm I.D.

glass column packed with 5% OV-17 on acid washed DMCS treated
chromosorb W(80-I00 mesh) and a 2m x 2.5cm I.D. glass column
packed with 3Í OV-225 on acid washed DMCS treated chromosorb
W(80-I00 mesh).

In all cases nitrogen was used as a carrier

gas at a flow rate of 20ml/mln. The Injector ports and detectors
were maintained at 240®C. Temperature programmed GC separations
were carried out at 8®C/mln. with an Initial temperature of 80^C.
Low resolution mass spectra were recorded on an EAI model
300D quadrupole mass spectrometer (Palo Alto, Calif., U.S.A.)
which had been Interfaced by means of a Watson-Bleman separator
to a Varían Model 600D gas Chromatograph (Walnut Creek, Calif.,
U.S.A.) fitted with a flame Ionisation detector. Operating conditions
for the mass spectrometer were as follows:

Ion source temperature

250®C, Ionising current 50 namp and Ionising voltage 70eV. The
III
Varían gas Chromatograph was fitted with a 8' x ^

O.D. stainless

steel column packed with 5% Aplezon N on DMCS treated chromosorb
W(80-100 mesh) and helium at a flow rate of 20ml/mln. was used.
The gas Chromatograph was set to a temperature programming mode

by means of a Varían Aerograph Linear Temperal'ure Prograinnjer
Model 300.

The mass spectrometer was Interfaced with a dedicated

Nova 1220 computer (Data General Corporation, U.S.A.).
Nuclear fnagnetlc resonance (NNS\) spectra were recorded on a
Hitachi Perkin Elmer R-24 High Resolution spectrometer (Norwalk,
Gonn., U.S.A.).
Optical rotations were measured on a Hllger Instrument using
0.5 dm, 5ml Polarimeter tubes.
Microanalysis were carried out by Dr. Challen of the
Chemistry Department, the University of New South Wales, N.S.W.,
Austral la.
Melting points were determined using a hot-stage mlcromeltlng point apparatus.
Tyrosine, tyramlne hydrochloride, N-acetyl tyrosine and
trlmethylanlIInlum chloride were supplied by B.D.H. Chemicals
Ltd., Poole, England.

Phenyl acetic-, phenyl lactic-, phenyl pyruvic-,

p-hydroxyphenyIacetic-, p-hydroxyphenyI lactic-, p-hydroxyphenyI pyruvic-,
4-ihydroxy-3-methoxypheny lacet Ic-, 4-hydroxy-3-methoxy-mande lie-,
2,5-dlhydroxyphenylacetlc-, 5-hydroxylndoleacetlc acids were
purchased from Sigma Chemical Co., (Missouri, Mo., U.S.A.).

The

biogenic amines such as dlhydroxyphenylalanlne (dopa),
dihydroxyphenylethylamine (dopamine), noradrenaline and adrenaline
were also obtained from Sigma Chemical

(Missouri, Mo., U.S.A.).

Plvaldehyde (2,2 dimethyfpropanal) and p-tosylsulphonylmethyl
nitrosamlde was obtained from Fluka AG Chemische Fabrik Buchs,

SwItzerIand.

BIs <trImethyIs11yI) trIf f uoroacetam f de (BSTFA)

was supplied by Pierce (Rockford, Ml,, U.S.A,), and also by
Regis Chemical Co., (Chicago, U.S.A.) In Iml or lOmI ampoules
stored under nitrogen.

Deuterium oxide (D2O) was supplied by

the Austral Ian Atomic Energy Commission (Lucas Heights, N.S.W.,
Australia).

Aluminium oxide was purchased from Merck Chemical

Co., (Darmstadt, Germany).

Molecular sieve type 3A (1/16"

pellets) was obtained from B.D.H. Chemicals Ltd., and by
Matheson, Coleman and Bell (East Rutherford, N.J., U.S.A.).
Standard solutions of tyrosine, tyramlne hydrochloride,
catecholamines and 2-amlno-n-octanolc acid were made up In
dilute hydrochloric a d d (0.1 N), while that of the phenolic
acids, N-acetyl tyrosine and adlplc acid were made up In
methanol.

The standard solutions were stored at 4^C In a

refrigerator, while the catecholamine solutions were kept In
a deep freeze.
Preparation of Dry Methanol
A dry round bottomed flask (1000 ml) was fitted with a
double surface condenser and a drying tube. Clean magnesium
turnings (2 g) and Iodine (0.2 g) were placed In the flask
followed by methanol (2.5 ml).

The mixture was warmed until

the Iodine had disappeared and some of the magnesium was
converted to the methylate.

More methanol (400 ml) was then

added and the mixture refluxed for 30 minutes.

The alcohol

was distilled off and stored over molecular sieve (3A).

Preparation of Trimethytan!Ilnlum Hydroxide (TMAH)
TrlmethylanlIInlum chloride (6.9 g) and silver oxide (6 g)
were stirred In anhydrous methanol (100 ml) for 2 hours.

The

solids were removed by filtration and several allquots were
titrated to a phenolpthalein end-point with H2S0i^ (0.100 N).
The hydroxide solution was adjusted to 0.40 N by suitable
dilution with methanol and was stored over molecular sieve (3A)
at O^C.
Preparation of Thlonyl Chloride-Methanol Reagent^^
Dry methanol (9 ml) was cooled In dry Ice/acetone and freshly
distilled thlonyl chloride (I ml) was added dropwlse.

The

reagent was kept In a stoppered flask at 0®C for up to 8 hours.
Preparation of Dlazomethane^^^
p-TosyI sulphonylmethyl nitrosamlde (4.3 g) was dissolved
In diethyl ether (60 ml) and the solution was cooled In Ice.
A cold solution of KOH (0.8 g In 20 ml 95% alcohol) was added
until the precipitate just dissolved.
in a refrigerator for 10 minutes.

The solution was placed

After this period of time,

the reaction mixture was distilled on a warm water bath, and
the diazomethane and ether was collected In a conical flask at
O^C.

The solution of diazomethane was capped tightly and the

reagent was kept In a deep freeze for up to 48 hours.
Preparation of N-Acetyl TyrosIne^^
N-acetyl tyrosine was made by treating a chilled solution
of L-tyrosine (15 g) in NaOH (42.5 ml, 2N) in water (25 ml).

This was again diluted further with NaOH (200 ml, 2N) and acetic
anhydride (20 ml).

After standing at room temperature for I hour,

sulphuric acid (84 ml, 6N) was added.

The mixture was evaporated

to dryness In vacuo and the residue was extracted several times
with acetone.

The combined acetone extracts were filtered and

the filtrate evaporated with nitrogen to a thick syrup.
Crystallisation was affected by rubbing the syrup with a little
cold water.

A yield of 13 g of N-acetyl tyrosine with melting

point I52-I54®C was obtained.
Derlvatlsatlon of Tyrosine for GC^MS
(I)

Preparation of 0-TrlmethyIsllyI NeopentyIIdene Tyrosine
methyl ester
Tyrosine was esterI fled with thlonyl chlorlde-methanol reagent

(I ml, lOi) by heating under reflux for 45 minutes, or by heating
In a screw-capped vial at 95®C for 60 minutes.

After evaporation,

derlvatlsatlon was completed by the addition of pyridine (300 pi),
pivaldehyde (50 pi), trlethylamine (100 pi) and a few sticks of
molecular sieve (type 3A).

After standing for 30 minutes at 70®C,

BSTFA (100 pi) was added.

After standing for a further 30 minutes,

an aliquot of the sample (2 pi) was Injected Into the (5C. The
derivative of tyrosine chromatographed as a single symmetrical
peak on a 3% Aplezon N column with a retention time of 27.3
minutes at 290®C using a temperature program of 8®C/mlnute with
an Initial temperature of 80®C.

The mass spectrum (Figure 7a)

showed a molecular Ion at m/e 335 (< IJt),an abundant Ion at 179

(CHa-CgHs-OSIMea) and fragmentations Involving losses of 57
C-C(CH3)3ll, and 59 (COOCHa) from the molecular Ion at 278 a^m.u.
and 276 a.m.u, respectively.
(II)

Preparation of 0-Methyl NeopentyIIdene Tyrosine Methyl
Ester by Pyrolytic MethylatIon
Tyrosine was dissolved In methanolIc TMAH (100 pi, 0.4 N)

and pivaldehyde (10 pi) In the presence of molecular sieve (type
3A). The vial was warmed at 60®C for 60 minutes and an aliquot
of the sample (2 pi) was Injected Into the GC. The derivative
chromatographed as a single symmetrical peak on a 5% Aplezon N
column with a retention time of 26.1 minutes at 270®C. The GC
separations were carried out by running Isothermally for I
minute at 80^C and then programming at 8®C/mInute to 300®C.
The mass spectrum of the derivative showed that the tyrosine
was converted to an 0-methyl ether derivative (Figure 7b)
with characteristic mass spectrum featuring a doublet two
mass units apart, corresponding to losses of the Isobutyl side
chain (57 mass units) at 220 a.m.u. and the methyl ester function
(59 mass units) at 218 a.m.u. The molecular Ion at 277 a.m.u.
was small (< li)- The most Intense mass fragment was the
substituted tropyllum Ion fragment at 121 a.m.u. and the loss
of this fragment from the molecular Ion (M"*" - 121) at 156 a.m.u.
Preparation of Deuterated Tyrosine by Group VIII Metal-Catalysed
Exchange^^
Reduced platinum catalyst (80 mg) was placed Into a pyrex

Vacuum
Line

Tap T

Preconstrlcted and
sealed here

Reagents

Figure 20. Reaction Tube for Exchange Reactions,

reaction tube and tyrosine (80 mg) was dissolved In deuterium
oxide (8 ml). The reaction mixture was frozen In an acetonedry Ice bath, and the reaction tube was evacuated to a pressure
of 0,005 torr.

After the usual degassing procedures, the sample

was allowed to attain room temperature under vacuum with the
tap closed (Figure 20).

After re-freezIng and re-evacuatIng,

the pyrex tube was sealed at the point where It had been
preconstrlcted to a capillary.

The reaction tube was cooled

and the seal was broken after 4 days. The labelled tyrosine
was completely dissolved by the addition of more D2O and the
metal catalyst was then removed by filtration. The filtrate
was adjusted to pH 5.5 with HCI and the solution was cooled
In Ice water. The precipitated tyrosine was collected by
filtration and the product was dried In a desslcator. The
labelled tyrosine was examined by GC-MS using the 0-methyl
ether of the neopenty11 dene tyrosine methyl ester derivative
(Method I D .

The total deuterium content of the derivative

at equilibrium was 67$ In the aromatic ring, but It contained
30$ dl- and 16$ tetra-deuterated species.
Preparation of Deuterated Tyrosine by AcId-Catalysed Exchange
Oeuterated tyrosine was prepared by refluxing tyrosine
(10 g) In deuterium oxide (100 ml) made 3-4 N through the
addition of HCI gas. The equilibrium of the reaction was
reached after 4 hours^

After cooling to O^C, the tyrosine

was precipitated by adjusting the solution to pH 5.5 with

ammonia (2N).

The precipítate was collected by filtration and

the tyrosine was crysta111 sed from a minimal quantity of
boiling water.

The crystals were filtered off, washed with

ethanol and dried In a desslcator.

The Identity of the product

was confirmed by GC-MS as tyrosine containing two deuterium
atoms In the aromatic ring.

The positions of the deuterium

atoms In the aromatic ring were shown to be ortho to the
hydroxy I function by nuclear magnetic resonance (NMR)
spectroscopy.

The 4 proton quartet at Í6.92 in the undeuterated

tyrosine was converted to a 2 proton singlet In the deuterated
sample (Figure 5).
Mass Fragmentometry of Deuterated Tyrosine Analysed as the 0-Methyl
NeopentylIdene Tyrosine Methyl Ester Derivative
The deuterated tyrosine prepared by exchange reactions In
heavy water (D2O) was derlvatlsed by the pyrolytic methylatlon
method.

This derivative was analysed by gas chromatography-mass

fragmentometry.

The relative mass Intensities of the Ions 121,

122 and 123 a.m.u. were listed by the computer for 6 mass spectral
recordings.

These were averaged and the percent deuterium content

was calculated to be 80Í D2-specles, I9ít Dx-specles and the
remainder \% Do-specles.
Back-Exchange of Deuterium from Deuterated Tyrosine during
Acid-Catalysed EsterlfIcatlon
Deuterium label led tyrosine (I mg) was esterlfled by heating
with thionyl chlorlde-methanol reagent (I ml, IOÍ) In a screw-

capped vial at 95®C for 60 minutes. The solvent was removed
under a stream of dry nitrogen and the tyrosine methyl ester
hydrochloride was derlvatlsed with pivaldehyde and BSTFA.

This

derivative was analysed by gas chromatography-mass fragmentometry.
The relative mass Intensities of the Ions at 179, 180 and 181 a.m.u
were determined.

The percent deuterium was calculated to be I9i.

This Is to be compared with a value of 80i as determined by mass
fragmentometry of the Ions 121, 122 and 123 mass units from the
0-methyl neopentylldene tyrosine methyl ester derivative.
Stability of Deuterated Tyrosine In I N Hydrochloric Acid
Since deuterium labelled tyrosine was syntheslsed by
exchange In acid conditions, the possibility of back exchange
was Investigated by Incubating deuterated tyrosine (2 mg) In
HCI <2 m l , IN) at 38°C. After a period of 24 hours, the mixture
was dried and the deuterated tyrosine was examined by preparation
of the 0-methyl neopentylldene tyrosine methyl ester derivative
and mass fragmentometry of the Ions 121, 122 and 123 a.m.u.

The

tyrosine showed no loss of the label under these conditions.
Quantitative Determination of Free Tyrosine and p-Tyramlne In
Urine
2-Amlno-n-octanolc acid (100 pg) was added as an Internal
standard to the urine (I ml) and the solution was acidified to
pH 2-3 with HCI (2 drops, 6N). The urine was then passed
through a column of cation exchange resin (Blorad AG 50W-X2,
100-200 mesh, 500 mg wet weight, H"*" form) and the a)lumn was

washed with water (15 ml).

The amino acids were eluted with

aqueous ammonia (30 ml, 2N) and the eluate was dried under
vacuum at 40°C.

The last traces of water were removed by the

addition of small amounts of benzene and re-evaporating.

The

dried residue was derlvatised for quantitative gas chromatographic
analysis by refluxlng with thlonyl chiorIde-dry methanol reagent
(I ml, IOÍ) for 45 minutes.

After evaporation, derivati satIon

was completed by the addition of dry pyridine (300 pi),
plvaldehyde (50 yl), triethylamine (100 yl) and molecular sieve
(type 3A).

The mixture was kept In a stoppered container at

IQPc for 30 minutes.

BSTFA (100 yl) was added.

After standing

for a further 30 minutes, an aliquot of the sample (2 yl) was
injected Into the gas chromatograph.
always obtained between duplicates.

Excellent agreement was
The recovery of tyrosine,

p-tyramlne and 2-amlno-n-octanoic acid by the above procedure
was checked by extracting urine samples spiked with known
amounts of each of these compounds and derlvatlslng the extract.
The percentage recovery exceeded 95% as determined by GC peak
height measurements.
A part of the dried amino acid extract was derlvatised for
the measurement of the deuterium content of tyrosine by
treatment with TMAH In anhydrous methanol (100 y I, 0.4N) and
plvaldehyde (10 y I) In the presence of molecular sieve (type 3A)
and pyrolytlcally esterlfylng the salt In the Injector port of
the GC prior to GC-MS.

Petermlnation of Urinary Conjugated Tyrosine
The method used was based on that described by Kaklmoto and
Armstrongl^O In which the Initial effluent and washings from the
cation exchange resin column were collected.

After the addition

of the Internal standard, 2-amlno-n-octanoIc acid (100 pg), the
solutions were hydrolysed In HCI (6N) at lOO^C for 3 hours.

The

hydrolysates were dried under vacuum (40°C) and were then
extracted and derlvatlsed for GC analysis In the same manner as
described for free tyrosine and p-tyramlne.
The recovery of N-acetyl tyrosine (NAT) and p-tyramine was
checked as before by spiking urine samples with these compounds.
In these experiments NAT was added to the urine prior to the
Initial Ion exchange treatment, whilst p-tyramlne was added to
the urine Ifnmedlately prior to hydrolysis.

The percentage

recovery of these two compounds exceeded 90% as determined by
GC using peak height measurements.
Measurement of Deuterium Content of Serum Tyrosine
For the measurement of deuterium content of serum tyrosine,
serum samples (100 pl> were deprotelnised by the addition of
ethanol (400 nl) followed by centrlfugatlon, after which the
supernatant was drawn off and evaporated with nitrogen.

The

dried residue was derlvatlsed by treatment with TMAH In
anhydrous methanol (100 pi, 0.4N) and plvaldehyde (10 vl) in
the presence of molecular sieve (type 3A) and pyrolytical ly
esterlfying the salt In the Injector port of the GC prior to

GC-MS.
Quantitative Determination of Tyrosine In Serum^^^
Water (1.5 ml) was added to serum (0.5 ml) and the solution
was deprotelnlsed with trichloroacetic a d d (TCA) (0.5 ml, 30?).
After centrlfugatlon, nitroso-naphthol (0.5 ml, O.li In 95%
ethanol) and nitric acid reagent (0.5 ml, 0.5 mg sodium nitrite
In I ml 20% nitric acid) were added to the supernatant (I ml)
In a stoppered centrifuge tube.

The stoppered tube was then

heated In a water bath at 55®C for 30 minutes, after which It
was allowed to cool and redistilled ethylene dlchlorlde (5 ml)
was added to the mixture.

The mixture was shaken for a few

minutes and then centrlfuged at low speed.

The top layer was

read at 450 nm against a reagent blank prepared In a similar
fashion to that of serum, except water was used instead of
serum.

The concentration of serum tyrosine was obtained by

comparison with suitable standards.
tsotatlon and Quantitative Determination of Urinary Phenolic
Aclds^^
Adipic acid (100 pg) was added as an Internal standard to
urine (I ml) and the solution was acidified to pH I with HCI
(0.1 ml, 6N) and then saturated NaCI (2 ml) was added.

The

mixture was extracted with ethyl acetate (3 x 2 ml) and
diethyl ether (3 x 2 ml) and the organic layers were pooled
and dried over anhydrous magnesium sulphate.

After filtration,

the solution was evaporated to dryness with dry nitrogen.

The

dried residue was derfvatlsed for quantitative gas chromatographic
analysis by sllylatlng with BSTFA (100 pi).
To ensure quantitative recoveries of phenolic acids, the
urines were extracted as quickly as possible following collection.
GC response factors were determined using authentic compounds
which had been stored at -20®C. The recovery of p-hydroxypheny I acetic
acid, p-hydroxy phenyl lactic acid, p-hydroxypheny I pyruvic acid and
adipic acid from urine was checked as before by spiking urine
samples with known amounts of each compound. Recoveries which
exceeded 95$ were determined by GC peak height measurements of
the derivatives.
urines.

Duplicate extracts were prepared for all

In all cases, excellent agreements between duplicates

were obtained.
Per I vat 1 sat I on of Phenolic Aclds^**
(i) Preparation of Phenolic Acid Methyl Esters by Pyrolytlc
MethylatIon
Derivatives of the phenolic acids were prepared by adding
trimethylanlllnlum hydroxide (0.2 ml, 0.4N) to the dried urinary
extract.

After standing for 30 minutes, a sample (2 yl) was

injected Into the GC. The retention time data and mass spectral
properties suitable for the Identification of urinary phenolic
acids are shown in Tables 3 and 4.
(II)

Preparation of Trlmethylsllyl Derivatives of Phenolic Acids
BSTFA (100 yl) was added to the dried urinary residue

(from I ml urine) and the solution was warmed to 60®C. After

Standing for 30 mfnutes, a sample (2 pi) was Injected Into the
GC, fitted with a glass column packed with 356 Aplezon N.

The

retention time data for the phenolic acids, pHPAA, pHPLA and
pHPPA are shown In Table 16 and the mass spectra of these
derivatives are shown In Figure 13 a, b and c respectively.
Table 16.

GC Retention Data'^ for Phenolic Acids

,, - ..
Phenolic Acid

Retention Time

Temperature
^OQ)

p-hydroxyphenyI acetic acid

13,45

170

p-hydroxyphenyI lactic acid

16.70

198

p-hydroxyphenyI pyruvic acid

17.00

201

+

Chromatographed Isothermal ly for I minute at 80°C and then
programmed at 8°C/mlnute.

Measurement of Deuterium Content of Phenolic Acids
The samples which had been analysed by gas chromatography
for quantitation of the phenolic acids were again analysed by
gas chromatography-mass fragmentometry for the measurement of
the deuterium content.

An appropriate Ion which contained the

phenolic ring moiety was selected and monitored and several
measurements were made of the heights of this Ion and its +1
and +2 peaks.

For p-hydroxyphenyIacetic acid and p-hydroxyphenyI

lactic acid, the m/e 179, 180 and 181 Ions were monitored.

For

p-hydroxypheny1 pyruvic acid, the m/e 325, 326 and 327 Ions were
nKjnltored.

Calibration Curve for Phenylacetic Acid, 4-hydroxy-phenyI acetic
acid and 4-hydroxy-3-methoxy phenyiacetic acid
Phenylacetic acid, 4-hydroxyphenyIacetic acid and 4-hydroxy3-methoxy phenylacetic acid (100 yl of 0.5, 1.0, 1.5, 2.0 and
2.5 X ld"^mM) were derlvatlsed In turn with methanol Ic TMAH
(O.f ml, 0.4M).

A sample (2 pi) was then Injected Into the

gas chromatograph and a graph of peak height against concentration
was plotted (Figure 10).
Preparation of Alumina for Adsorption of Catecholamines
Alumina (100 g) was added to HCI (500 ml, 2N) In a 1000 ml
pyrex beaker covered with a watch glass and the suspension was
stirred on a combination magnetic stirrer and hot plate at 90tOO^C for 45 minutes.

The beaker was then removed from the hot

plate-stlrrer and the heavy particles of aluminium oxide were
allowed to settle for

minutes.

The distinctly yellow

supernatant fluid was discarded along with the finer particles
of aluminium oxide.

The precipitate was then washed with HCI

(2 x 250 ml, 2N) by heating to 70®C for 10 minutes and discarding
the supernatant each time.

In the final acid wash, the aluminium

oxide was stirred with HCI (500 ml, 2N) at 50®C for 10 minutes.
After decanting the HCI, the precipitate was washed repeatedly
with distilled water (25 x 200 ml) until the pH was close to 3.4.
Finally/the aluminium oxide was heated to I20^C for ! hour,
200®C for 2 hours In an evaporating dish and then stored at 37^C
to exclude moisture.

This heat treatment step was found to be

Important, since untreated aluminium oxide has a reduced adsorption
efficiency (approximately 85% of treated).

Before use, each batch

of acid washed alumina was tested for recovery of standard
catecholamines from spiked urine samples and It was used only If
the recoveries of the standards were greater than 85$.
Determination of Urinary Catecholamines
All urines collected for catecholamine assays were acidified
and frozen as soon as possible.

The urine (50 ml) was filtered

through a Whatman No. I filter paper and the specially activated
alumina (0«5 g) and the sodium salt of EDTA (5 ml, 0.2M) were
added.

The pH of the suspension was adjusted with NaOH-ascorblc

acid (7 volumes of NaOH (5N) and 3 volumes of ascorbic acid (li)
prepared Immediately before use) to a pH 8.5 using a Radiometer
pH meter.

After stirring for a few minutes, the alumina and

urine were transferred quantitatively to a chromatographic column.
The alumina was then washed with water (20 ml) and the catecholamines
were then eluted with acetic acid (10 ml, 0.4N).

The acetic acid

eiuate containing the catecholamines was dried under vacuo or
freeze dried.
PerIvatIsatIon of the CatchoIamines
Volatile derivatives of the freeze dried catecholamine extract
were prepared by the addition of trlfluoroacetlc anhydride (0.2 ml)
and heating the reaction mixture to 60-70®C for 10 minutes In a
capped vial.

After this time, the reagent was blown off In a

stream of dry nitrogen In an exhaust hood and the residue was

dissolved In dry methanol (0.1 ml).

The solution was heated at

60-70®C for 10 minutes and the methanol was then blown off
completely and the residue was treated with BSTFA (30 yl) at
60-70®C for 10 minutes.

A sample (5 yl) was then Injected into

a gas Chromatograph fitted with an OV-225 glass column.

The

retention time data for the catecholamines, dopamine, noradrenaline,
adrenaline and dopa are shown In Table 17, and the mass spectra
of these derivatives are shown In Figure 15.
Table 17. GC Retention Data for Catecholamines

Retention Time
(min)

Temperature
(^C)

Dopamine

6.0

Isothermally

NoradrenalIne

7.2

200®C

Adrenaline

9.5

Catecholamine

Dopa

12.0

Measurement of Deuterium Content of Catecholamines
Because of the low concentration of the catecholamines In
urine, quantitation of these were not made, but the deuterium
content of dopamine and noradrenaline were determined.

An

appropriate Ion which contained the aromatic ring moiety was
selected and monitored and several measurements were made of
the heights of this Ion and Its •••I peaks.

For dopamine, m/e 267

and 268 were monitored, while the Ions 297 and 298 were monitored

for noradrenaline.
Calibration Curve for Dopamine and Noradrenaline
Dopamine and noradrenaline (100 yl of 0,5, 1.0, 1.5 and
2.0 X lO^'^mM) were derlvatlsed In turn by the procedure
described (Section:

Deri vatI satIon of Catecholamines).

A

2 pi sample was Injected Into the gas chromatograph and the
peak height response was plotted against the concentration
(Figure 16).
Estimation of Creatinine
#

Urinary creatinine estimations were carried out on the
Technlcon Auto-Analyzer by the Procedure N-llb. This automated
procedure for measuring creatlnlne^**^»^**^ Is based on the reaction
between plcrate and creatinine (Jaffe reaction).

The diluted

urine sample segmented with air and diluted with sodium chloride
(l.8i) was dialysed Into segmented distilled water.

After

emerging from the dlalyser, the diluted creatinine was mixed with
NaOH (0.5 N).

Picric acid (l.3i) was added to the stream and the

three components were mixed.

The absorbance of the analytical

stream was measured at 505 nm In a 15 mm flowcell.

tot

Protocol for Deuterated Tyrosine Loading Experiment on the Control
The procedure for the experiment on the control on an oral load
of 663 ymoles deuterated tyrosIne/kg body weight was carried out
as shown below.

Time

Procedure

0900

Blood and urine (U ) collected
for BASELINE Ieve IS.

0900

663 ymoles deuterated tyrosIne/kg

Total Volume (ml)
80

body weight was given orally.
1015

Urine collected (Uj).

40

1030

Blood taken for serum tyrosine.

1500

Urine collected (U2).

1630

Blood collected for serum tyrosine.

2100

Urine collected (U3).

150

2400
Next day

Urine collected (U^).

130

0300

Urine collected (U5).

400

0800

Urine collected (U^).

400

1400

Urine collected (U^).

221

iirlne collected (Ug).

904

171

Next day
0900

Protocoi for Deuterated Tyrosine Loading Experiment on P.R.
The procedure for the experiment on P.R. on an oral load of
663 ymoles deuterated tyrosine/kg body weight was carried out
as shown below.

Time

Procedure

0900

663 pmoles deuterated tyrosine/
kg body weight was given orally.

1009

Blood taken for serum tyrosine.

1030

Urine collected (Uj).

176

1500

Urine collected (U2).

64

1630

Blood taken for serum tyrosine.

2130

Urine collected (U^).

Total Volume (ml)

154

Next day
0105

Blood taken for serum tyrosine.

0900

Urine collected (U^).

1800

Blood taken for serum tyrosine.

500

Protocol for Deuterated Tyrosine Loading Experiment on J.L,
A flow sheet for the experiment on J A . on an oral load of
663 pmoles/kg body weight was carried out as shown below.

Time

Procedure

0900

Blood taken for baseline serum
tyrosine.

0940

Urine collected for BASELINE, divided
Into 2 halves. 1 In HCI (6N) for
catecholamines. Other half In plain
bottle for organic acids (UQ).

Total Volume (ml)

140

0945

663 pmoles deuterated tyroslne/kg
body weight made up with orange
flavouring was given orally.
Breakfast was given as usual after
this tyrosine load.

1145

Blood taken for serum tyrosine.
Urine collected (Uj).

1415

Urine collected <U2>.

120

1625

Urine collected (U3).

99

1750

Blood taken for serum tyrosine.

1850

Urine collected (U^).

152

2100

Urine collected (U^).

214

0845

Urine collected (U^).

900

0945

Blood taken for serum tyrosine.

1000

Urine collected (U^).

197

1500

Urine collected (Ug).

280

1900

Urine collected (U^).

223

2300

Urine collected <U|Q).

323

74

Next day

(cont'd)
Next day
0600

Urine collected

555

0900

Urine collected

188

1030

Blood taken for serum tyrosine.

Protocoi for Deuterated Tyrosine Loading Experiment on J.L>
A flow sheet for the experiment on J A . on a reduced oral load
of 221 ymoles deuterated tyroslne/kg body weight was carried
out as shown below*

Time

Procedure

1015

221 ymoles deuterated tyroslne/kg
body weight was given orally.

1150

Urine collected

1215

Blood taken for serum tyrosine.

1415

Blood taken for serum tyrosine.

1445

Urine collected (U2).

208

1800

Urine collected

316

2230

Urine collected (U4).

307

1000

Urine collected

465

1015

Blood taken for serum tyrosine.

1230

Urine collected (Ug).

101

1440

Urine collected

125

1745

Urine collected (Uq).

91

0600

Urine collected (Ug).

690

0930

Urine collected (U.Q).

104

Total Volume (ml)

186

( U 3 ) .

Next day
( U 5 ) .

Next day

Protocol for Deuterated Tyrosine Loading Experfmenl' on P>R«
The procedure for the experiment on P.R, on a reduced oral
load of 221 ymoles deuterated tyrosine/kg body weight was
carried out as shown below.

Time

Procedure

Total Volume (ml)

0900

Blood taken for serum tyrosine.
221 umoles deuterated tyroslne/kg body wt
was given orally.

ItOO

Blood taken for serum tyrosine.

1215

Urine collected (Uj).

1300

Blood taken for serum tyrosine.

1320

Urine collected (U2).

24

1600

Urine collected

79

1700

Urine collected (U^).

39

1850

Urine collected

37

1930

Urine collected

14

0630

Urine collected

151

0900

Blood taken for serum tyrosine.

0940

Urine collected

1215

Urine collected (U9).

27

1415

Urine collected

23

1900

Urine collected

143

0900 +
1 week

Blood taken for serum tyrosine.

( U 3 ) .

( U 3 ) .

49

Next day

( U 3 ) .

28

Calculation of Results from Deuterated Tyrosine Loading Experiment
The experiment with P.R. on an oral load of 663 pmoles of
deuterated tyroslne/kg body weight was used to Illustrate how
results In Tables 5, 6, 7, 9 and 10 were derived»
Total amount (ymoI/kg body weight)
The total amount of tyrosine and Its metabolites, pHPAA,
pHPLA and pHPPA were derived from peak ratios (metabolites/
adfpic acid as Internal standard) measured off a standard graph
prepared In a similar fashion.

These results were then expressed

as the total amount In each urine sample/kg body weight (Figure 7).
Deuterium (Content (% D2-specles)
Because no baseline urine was collected prior to deuterated
tyrosine load In this particular experiment, standard tyrosine
and standard phenolic a d d s were used to establish the natural
relative Intensities of the +1 and +2 contribution to the Ions
of Interest.

The results were expressed as the percentage the

02-specles represented of the total (D2 x IOO/DQ + OX + D 2 ) , and
a correction was made for the Intensity of the D2 satellite Ion
In the non-deuterated compound.

(Figure

7).

Total Amount D2-specles excreted (pmol D2-metabolItes/kg body
weight)
The quantity of recovered deuterated tyrosine or deuterated
phenolic metabolIte In ymol/kg body weight, was then calculated
by multiplying the % deuterium label by the total amount of
metabolite present In the sample.

Total Amount D9-metaboiites (mumol D2-metabolIte/kg body weight/
ml urine)
These figures were derived from total amount D2-metabolItes
excreted In mpmol/kg body weight and expressed as, per ml of urine
Total Amount D2-metabolIte excreted (pmol/kg body welght/mmol
creatinine)
Again these figures were derived from total amount D2metabollte excreted In |imol/kg body weight and expressed as,
per mmol creatinine.
Preparative EsterlflcatIon of Carboxyllc Acids via Pyrolytlc
Methylatlon^38

(a)

Preparation of Benzoic Acid Methyl Ester
A solution of benzoic acid (2g, 0.016 mol) In methanol

(5 ml) was titrated with methanoUc trlmethylanlIInlum hydroxide
(0.85 mol) to a Phenolphthalein end-point (19 ml).

After removal

of the methanol In vacuo, the residue consisting of the
trlmethylanlIInlum salt was redlssolved In toluene (6 ml), and
the solution was heated under reflux for 30 minutes.
Qf

Traces

Moj-eacted a d d were removed by extraction of the toluene

solution with water.

Final purification was affected by

distillation under reduced pressure.

A yield of 90? (1.95 g)

boiling at 198-200^0 was obtained.
Found:

C, 70.56;

Calculated for

H, 5.93$

C8H8O2:

C, 70.82;

H, 6.12?

^^^

^^eparation of 2, 4, 6, Trimethyl Benzoic Acid Methyi Ester
Trimethyl benzoic acid (1.0 g) was treated In the same

manner as described above to give trimethyl benzoic acid
methyl ester.

A yield of 92Ì (0.99 g) boiling at II5®C at

8 torr was obtained.
Found:

C, 74.25;

Calculated for
ic)

H, 7.92

CiiHm02:

C, 74.16;

H, 7.87

Preparation of m-Hydroxy Benzoic Acid Methyl Ester
m-Hydroxy benzoic acid (1.0 g) was treated as described

above to yield m-methoxy benzoic acid methyl ester.

A yield

of 85i (0.93 g) boiling at I2I-I25®C at 10 torr was obtained.
Found:

C, 65.14;

Calculated for
(d)

H, 5.98

C9H10O3:

C, 65.06;

H, 6.02

Preparation of I-Naphthalene Acetic Acid Methyl Ester
I-Naphtha lene acetic acid (1.0 g) was esteri fled as

described above to give l-naphthalene acetic acid methyl ester.
A yield of 88Ì (0.94 g) boiling at I65-I67^C at 10 torr was
obtained.
Found:

C, 78.21;

Calculated for
(e)

H, 6.10

CX3H12O2:

C, 78.00;

H, 6.00

Preparation of Myrlstic Acid Methyl Ester
Myrlstic acid (1.0 g) was esteri fled as described to give

myrlstic acid methyl ester.

A yield of 88Ì (0.96 g) boiling

I55-I58®C at 10 torr was obtained.
Found:

C, 74.52;

Calculated for

H, 12.52

C15H30O2:

C, 74.38;

H, 12.40
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